ES2242291T5 - Análogos de nucleósidos bicíclicos y tricíclicos, nucleótidos y oligonucleótidos - Google Patents
Análogos de nucleósidos bicíclicos y tricíclicos, nucleótidos y oligonucleótidos Download PDFInfo
- Publication number
- ES2242291T5 ES2242291T5 ES98942516.0T ES98942516T ES2242291T5 ES 2242291 T5 ES2242291 T5 ES 2242291T5 ES 98942516 T ES98942516 T ES 98942516T ES 2242291 T5 ES2242291 T5 ES 2242291T5
- Authority
- ES
- Spain
- Prior art keywords
- lna
- reaction
- group
- primer
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Description
Para la persona especialista en la técnica estará claro que los ejemplos específicos antes mencionados como intercaladores del ADN, grupos fotoquímicamente activos, grupos termoquímicamente activos, grupos quelantes, grupo informadores, y ligandos, corresponden a la parte activa/funcional de los grupos en cuestión. Para la persona 5 formada en la técnica, está adicionalmente claro que los intercaladores del ADN, grupos fotoquímicamente activos, grupos termoquímicamente activos, grupos quelantes, grupo informadores, y ligandos, se representan típicamente en la forma M-K-, en donde M es la parte activa/funcional del grupo en cuestión, y en donde K es un espaciador a través del cual se une la parte “activa/funcional” al anillo de 5 miembros. Por tanto, debería entenderse que el grupo B, en los casos en que B se selecciona respectivamente de entre los intercaladores del ADN, grupos
10 fotoquímicamente activos, grupos termoquímicamente activos, grupos quelantes, grupos informadores, y ligandos, tiene la forma M-K-, en donde M es la parte funcional/activa del intercaladores del ADN, grupo fotoquímicamente activo, grupo termoquímicamente activo, grupo quelante, grupos informadores, y ligando, y en donde K es un espaciador opcional que comprende 1-50 átomos, preferiblemente 1-30 átomos, en particular 1-15 átomos, entre el anillo de 5 miembros y la parte activa/funcional.
15 En el presente contexto, el término espaciador significa un grupo que crea una distancia y no es termoquímica y fotoquímicamente activo, y que se usa para unir dos o más porciones diferentes de los tipos definidos más arriba. Los espaciadores se seleccionan en base a un variedad de características, incluyendo su hidrofobicidad, hidrofilicidad, flexibilidad molecular y longitud (por ejemplo, ver Hermanson et. al., Immobilized Affinity Ligand
20 Techniques, Academic Press, San Diego, California (1992), pp. 137-ff). Generalmente, la longitud de los espaciadores es inferior a 100 angstroms, en algunas aplicaciones preferiblemente menos de 100 angstroms. Por tanto, el espaciador comprende una cadena de átomos de carbono, opcionalmente interrumpida o terminada con uno o más heteroátomos, tales como los átomos del oxígeno, átomos del nitrógeno, y/o átomos de azufre. Por tanto, el espaciador K podría comprender una o más funcionalidades amida, éster, amino, éter, y/o tioéter, y opcionalmente
25 hidrocarburos aromáticos o mono/poliinsaturados, polioxietilenos tales como el polietilenglicol, oligo/poliamidas tales como la poli-β-alanina, poliglicina, polilisina, y péptidos en general, oligosacáridos, oligo/fosfatos. Más aún, el espaciador podría consistir en unidas del mismo combinadas. La longitud del espaciador podría variar, tomando en consideración la ubicación y orientación espacial deseadas o necesarias de la parte activa/funcional del grupo en cuestión en relación al anillo de 5 ó 6 miembros. En realizaciones particularmente interesantes, el espaciador incluye
30 un grupo cortable químicamente. Los ejemplos de tales grupos químicamente cortables incluyen los grupos disulfuro, que pueden cortarse químicamente en condiciones reductoras, los fragmentos de péptidos cortables mediante peptidasas, etc.
En una realización de la presente invención, K designa un enlace sencillo, de forma que la parte funcional/activa del 35 grupo en cuestión está unida directamente al anillo de 5 miembros.
En una realización preferida, el sustituyente B es las Formulas I y II generales se selecciona preferiblemente de entre las nucleobases, en particular, de entre adenina, guanina, timina, citosina y uracilo.
40 En los oligómeros de la presente invención (Fórmula I), P designa la posición del radical para un enlace internucleósido con un monómero sucesivo, o un grupo 5'-terminal. La primera posibilidad se aplica cuando el LNA en cuestión no es el monómero 5'-terminal, mientras que la última posibilidad se aplica cuando el LNA en cuestión es el monómero 5'-terminal. Debería entenderse (lo que también estará claro a partir de la definición más adelante de enlace internucleósido y grupo 5'-terminal) que un enlace internucleósidos o grupo 5'-terminal puede incluir el
45 sustituyente R5, formando de ese modo un doble enlace con el grupo P. (5'-terminal se refiere a la posición correspondiente al átomo de carbono 5' de un grupo ribosa en un nucleósido).
Por otra parte, un enlace internucleósido con un monómero precedente o un grupo 3'-terminal (P*) podría originarse a partir de las posiciones definidas por el sustituyente R3* .
50 Análogamente, la primera posibilidad se aplica cuando el LNA en cuestión no es el monómero 3'-terminal, mientras que la última posibilidad se aplica cuando el LNA en cuestión es el monómero 3'-terminal. (3'-terminal se refiere a la posición correspondiente al átomo de carbono 3' de un grupo ribosa en un nucleósido).
En el presente contexto, el término monómero se refiere a nucleósidos que ocurren de forma natural, a nucleósidos
55 que no ocurren de forma natural, PNA, etc., así como a LNA. Por tanto, el término monómero sucesivo se refiere al monómero vecino en la dirección 5'-terminal y el monómero precedente se refiere al monómero vecino en la dirección 3'-terminal. Tales monómeros sucesivos y precedentes, vistos desde la posición de un monómero LNA; podrían ser nucleósidos que ocurren de forma natural o nucleósido que no ocurren de forma natural, o incluso monómeros de LNA adicionales.
10
activos, los grupos quelantes, los grupos informadores, y los ligandos (en donde los últimos grupos podrían incluir un espaciador tal como se definió para el sustituyente B).
En una realización preferida de la presente invención, el oligómero tiene la siguiente Fórmula V:
G-[Nu-L]n(0)-{[LNA-L]m(q)-[Nu-L]n(q)}q-G* V en donde, q es 1-50; cada uno de n (0), ..., n (q)es independientemente 0-10000; cada uno de m (1), ..., m (q)es independientemente 1-10000;
10 a condición de que la suma de n (0), ..., n (q) y m (1), ..., m (q) sea 2-15000; G designa un grupo 5'-terminal; cada Nu designa independientemente un nucleósido seleccionado de entre los nucleósidos que ocurren naturalmente y los análogos de nucleósido; cada LNA designa independientemente un análogo de nucleósido;
15 cada L designa independientemente un enlace internucleósido entre dos grupos seleccionados de entre Nu y LNA, o L junto con G* designa un grupo 3'-terminal; y cada LNA-L designa independientemente un análogo de nucleósido con la Fórmula I general tal como se definió más arriba, o preferiblemente con la Fórmula Ia general tal como se definió más arriba.
20 Dentro de esta realización, así como de forma general, la presente invención proporciona la intrigante posibilidad de incluir LNA con diferentes nucleobases, en particular, tanto nucleobases seleccionadas de entre timina, citosina y uracilo, y nucleobases seleccionadas de entre adenina y guanina.
En otra realización de la presente invención, el oligómero comprende además un PNA monómero o segmento de 25 oligómero con la fórmula,
30
35
40 en donde B es tal como se definió más arriba para la Fórmula I, AASC designa hidrógeno o una cadena lateral de aminoácido, t es 1-5, y w es 1-50.
En el presente contexto, el término cadena lateral de aminoácido significa un grupo unido al átomo α de un αaminoácido, es decir, correspondiente al α-aminoácido en cuestión sin la porción glicina, preferiblemente un α45 aminoácido que ocurre naturalmente o puede conseguirse fácilmente. Son ejemplos ilustrativos, el hidrógeno (la propia glicina), deuterio (glicina deuterada), metilo (alanina), cianometilo (β-ciano-alanina), etilo, 1-propilo (norvalina), 2-propilo (valina), 2-metil-1-propilo (leucina), 2-hidroxi-2-metil-1-propilo (β-hidroxi-leucina), 1-butilo (norleucina), 2butilo (isoleucina), metiltioetilo (metionina), bencilo (fenilalanina), p-amino-bencilo (p-amino-fenilalanina), p-iodobencilo (p-iodo-fenilalanina), p-fluoro-bencilo (p-fluoro-fenilalanina), p-bromo-bencilo (p-bromo-fenilalanina), p-cloro50 bencilo (p-cloro-fenilalanina), p-nitro-bencilo (p-nitro-fenilalanina), 3-piridilmetilo (β-(3-piridil)-alanina), 3, 5-diiodo-4hidroxi-bencilo (3, 5-diiodo-tirosina), 3, 5-dibromo-4-hidroxi-bencilo (3, 5-dibromo-tirosina), 3, 5-dicloro-4-hidroxibencilo (3, 5-dicloro-tirosina), 3, 5-difluoro-4-hidroxi-bencilo (3, 5-difluoro-tirosina), 4-metoxi-bencilo (O-metil-tirosina), 2-naftilmetilo (β-(2-naftil)-alanina), 1-naftilmetilo (β-(1-naftil)-alanina), 3-indolilmetilo (triptófano), hidroximetilo (serina), 1-hidroxietilo (treonina), mercaptometilo (cisteína), 2-mercapto-2-propilo (penicilamina), 4-hidroxibencilo (tirosina),
55 amino-carbonilmetilo (asparagina), 2-aminocarboniletilo (glutamina), carboximetilo (ácido aspartico), 2-carboxietilo (ácido glutámíco), aminometilo (ácido α, β-diaminopropiónico), 2-aminoetilo (ácido α, γ-diaminobutírico), 3-aminopropilo (ornitina), 4-amino-1-butilo (lisina), 3-guanidino-1-propilo (arginina), y 4-imidazolilmetilo (histidina).
El PNA monomérico o segmento de oligómero podría incorporarse en un oligómero tal como se describe en EP
14
Claims (13)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6 imagen7 imagen8 -
- 55.
- Utilización de oligómeros modificados con LNA (ribozimas), según cualquiera de las reivindicaciones 1 a 27, en el corte específico para la secuencia de ácidos nucleicos diana in vitro.
-
- 56.
- Utilización de un oligonucleótido modificado con LNA (un oligómero), según cualquiera de las reivindicaciones 1 a 27, en el diagnóstico para el aislamiento, purificación, amplificación, detección, identificación, cuantificación, o captura de ácidos nucleicos naturales o sintéticos.
-
- 57.
- Utilización, según la reivindicación 56, en la que el oligonucleótido comprende un grupo fotoquímicamente activo, un grupo termoquímicamente activo, un grupo quelante, un grupo informador, o un ligando que facilita la detección directa o indirecta del oligonucleótido o la inmovilización del oligonucleótido sobre un soporte sólido.
-
- 58.
- Utilización, según la reivindicación 56, en el que: el grupo fotoquímicamente activo, el grupo termoquímicamente activo, el grupo quelante, el grupo informador, o el ligando, incluyen un espaciador (K), comprendiendo dicho espaciador un grupo que puede cortarse químicamente.
-
- 59.
- Utilización, según la reivindicación 56:
- (a)
- para la captura y detección de ácidos nucleicos de doble hebra o hebra única, naturales o sintéticos, tales como el ARN o ADN; o
- (b)
- para la purificación de ácidos nucleicos de doble hebra o hebra única naturales, tales como el ARN o ADN; o
- (c)
- como una sonda para la hibridación in situ, hibridación en Southern, hibridación por transferencia en punto, hibridación por transferencia en punto inversa, o en hibridación Northern; o
- (d)
- en la construcción de un par de afinidad; o
- (e)
- como un cebador en una reacción de secuenciación de ácido nucleico o en reacciones de extensión con cebador; o
- (f)
- como un cebador en una reacción de amplificación de ácido nucleico.
- 60. Utilización, según la reivindicación 59(f), en la que:
- (i)
- dicha reacción de amplificación es una reacción PCR; o
- (ii)
- el cebador está adaptado de manera que la reacción de amplificación es una reacción esencialmente lineal; o
(iii) el cebador está adaptado de manera que la reacción de amplificación es una reacción esencialmente exponencial. -
- 61.
- Utilización, según la reivindicación 59 ó 60, en la que la reacción de amplificación del ácido nucleico da lugar a un producto de ADN de doble hebra que comprende al menos un extremo en hebra única.
-
- 62.
- Utilización in vitro de un oligonucleótido modificado con LNA (un oligómero), según cualquiera de las reivindicaciónes 1 a 27, (a) como un aptámero en el diagnóstico molecular, o (b) como un aptámero en los procesos catalíticos mediados por el ARN, o (c) como un aptámero en la unión específica de antibióticos, fármacos, aminoácidos, péptidos, proteínas estructurales, receptores proteicos, enzimas proteicas, sacáridos, polisacáridos, cofactores biológicos, ácidos nucleicos, o trifosfatos, o (d) como un aptámero en la separación de enantiómeros de mezclas racémicas mediante unión estereoespecífica, o (e) para marcar células, o (f) para hibridar ARN celular que no codifica proteínas, tales como el ARNt, el ARNr, el ARNsn y el ARNsc, o (g) para hibridar ARN celular que no codifica proteínas, tales como el ARNt, el ARNr, el ARNsn y el ARNsc, o (h) en la construcción de sondas Taqman o Balizas Moleculares.
-
- 63.
- Utilización, según la reivindicación 62, en el que la marca permite que las células sean separadas de las células no marcadas.
-
- 64.
- Equipo para el aislamiento, purificación, amplificación, detección, identificación, cuantificación, o captura de ácidos nucleicos naturales o sintéticos, comprendiendo el equipo un cuerpo de reacción y uno o más nucleótidos modificados con LNA (oligómeros), según una cualquiera de las reivindicaciones 1 a 27.
-
- 65.
- Equipo, según la reivindicación 64, en el que los nucleótidos modificados con LNA están inmovilizados sobre dicho cuerpo de reacción.
-
- 66.
- Oligonucleótidos de fosforomonotioato LNA total o parcialmente fosforilados, según cualquiera de las reivindicaciones 1 a 27, para utilizar en aplicaciones terapéuticas antisentido y en otras aplicaciones terapéuticas.
108
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK105497 | 1997-09-12 | ||
DK105497 | 1997-09-12 | ||
DK149297 | 1997-12-19 | ||
DK149297 | 1997-12-19 | ||
DK6198 | 1998-01-16 | ||
DK6198 | 1998-01-16 | ||
DK28698 | 1998-03-03 | ||
DK28698 | 1998-03-03 | ||
DK58598 | 1998-04-29 | ||
DK58598 | 1998-04-29 | ||
US8830998P | 1998-06-05 | 1998-06-05 | |
US88309P | 1998-06-05 | ||
DK75098 | 1998-06-08 | ||
DK75098 | 1998-06-08 | ||
DKPA199800982 | 1998-07-28 | ||
DK98298 | 1998-07-28 | ||
PCT/DK1998/000393 WO1999014226A2 (en) | 1997-09-12 | 1998-09-14 | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2242291T3 ES2242291T3 (es) | 2005-11-01 |
ES2242291T5 true ES2242291T5 (es) | 2016-03-11 |
Family
ID=27570781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98942516.0T Expired - Lifetime ES2242291T5 (es) | 1997-09-12 | 1998-09-14 | Análogos de nucleósidos bicíclicos y tricíclicos, nucleótidos y oligonucleótidos |
Country Status (13)
Country | Link |
---|---|
EP (5) | EP1557424A1 (es) |
JP (2) | JP4236812B2 (es) |
KR (1) | KR100414936B1 (es) |
CN (1) | CN1273476C (es) |
AT (1) | ATE293123T1 (es) |
AU (1) | AU9063398A (es) |
CA (1) | CA2303299C (es) |
DE (2) | DE69829760T3 (es) |
ES (1) | ES2242291T5 (es) |
HK (1) | HK1033946A1 (es) |
IL (5) | IL135000A0 (es) |
NZ (1) | NZ503765A (es) |
WO (1) | WO1999014226A2 (es) |
Families Citing this family (1013)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
USRE44779E1 (en) | 1997-03-07 | 2014-02-25 | Santaris Pharma A/S | Bicyclonucleoside and oligonucleotide analogues |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US6583168B1 (en) | 1997-11-25 | 2003-06-24 | Applera Corporation | Sulfonated diarylrhodamine dyes |
UA61997C2 (en) | 1998-05-26 | 2003-12-15 | Icn Pharmaceuticals | Nucleosides with bicyclic sugar constituent, oligonucleotide and antiviral pharmaceutical composition |
US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
JP2003511466A (ja) * | 1998-11-11 | 2003-03-25 | パンセコ・アクティーゼルスカブ | 修飾pna分子 |
US6548651B1 (en) | 1998-11-11 | 2003-04-15 | Pantheco A/S | Modified peptide nucleic acid (PNA) molecules |
CN1273478C (zh) | 1999-02-12 | 2006-09-06 | 三共株式会社 | 新型核苷及低聚核苷酸类似物 |
JP4148662B2 (ja) * | 2000-08-10 | 2008-09-10 | 第一三共株式会社 | ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬 |
JP5095888B2 (ja) | 1999-03-18 | 2012-12-12 | エクシコン エ/エス | 特異的lnaプライマによる遺伝子内における突然変異の検出 |
WO2000056920A1 (en) | 1999-03-18 | 2000-09-28 | Exiqon A/S | One step sample preparation and detection of nucleic acids in complex biological samples |
ATE465168T1 (de) * | 1999-03-18 | 2010-05-15 | Exiqon As | Xylo-lna analoge |
US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
US6639059B1 (en) | 1999-03-24 | 2003-10-28 | Exiqon A/S | Synthesis of [2.2.1]bicyclo nucleosides |
US6734291B2 (en) | 1999-03-24 | 2004-05-11 | Exiqon A/S | Synthesis of [2.2.1]bicyclo nucleosides |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
CN102180924A (zh) | 1999-05-04 | 2011-09-14 | 桑塔里斯制药公司 | L-核糖-lna类似物 |
US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
US6593466B1 (en) | 1999-07-07 | 2003-07-15 | Isis Pharmaceuticals, Inc. | Guanidinium functionalized nucleotides and precursors thereof |
JP4151751B2 (ja) | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
EP1224280A2 (en) * | 1999-10-04 | 2002-07-24 | Exiqon A/S | Design of high affinity rnase h recruiting oligonucleotide |
AU7406600A (en) * | 1999-10-04 | 2001-05-10 | Exiqon A/S | A method of increasing the specificity of oxy-lna oligonucleotides |
US20020068709A1 (en) * | 1999-12-23 | 2002-06-06 | Henrik Orum | Therapeutic uses of LNA-modified oligonucleotides |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
US6936467B2 (en) | 2000-03-27 | 2005-08-30 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
OA12240A (en) * | 2000-03-27 | 2006-05-10 | Univ Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides. |
ATE450621T2 (de) | 2000-03-30 | 2009-12-15 | Whitehead Biomedical Inst | Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind |
US6887664B2 (en) | 2000-06-06 | 2005-05-03 | Applera Corporation | Asynchronous primed PCR |
JP2002322192A (ja) * | 2000-08-10 | 2002-11-08 | Sankyo Co Ltd | 2’−o,4’−c−架橋ヌクレオシドトリリン酸体 |
WO2002028875A2 (en) * | 2000-10-04 | 2002-04-11 | Cureon A/S | Improved synthesis of purine locked nucleic acid analogues |
AU2002213125B2 (en) | 2000-10-11 | 2007-11-22 | Applied Biosystems, Llc. | Fluorescent nucleobase conjugates having anionic linkers |
US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
US6720148B1 (en) | 2001-02-22 | 2004-04-13 | Caliper Life Sciences, Inc. | Methods and systems for identifying nucleotides by primer extension |
EP1247815A3 (en) * | 2001-03-25 | 2003-01-29 | Exiqon A/S | Modified oligonucleotides and uses thereof |
WO2002079495A2 (en) | 2001-03-27 | 2002-10-10 | University Of Delaware | Genomics applications for modified oligonucleotides |
WO2002079467A2 (en) * | 2001-03-29 | 2002-10-10 | Københavns Universitet | Antibiotic-free bacterial strain selection with antisense molecules |
EP1251183A3 (en) * | 2001-04-18 | 2003-12-10 | Exiqon A/S | Improved helper probes for detection of a target sequence by a capture oligonucleotide |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
AU2002317437A1 (en) * | 2001-05-18 | 2002-12-03 | Cureon A/S | Therapeutic uses of lna-modified oligonucleotides in infectious diseases |
US7053195B1 (en) | 2001-06-12 | 2006-05-30 | Syngenta Participatious Ag | Locked nucleic acid containing heteropolymers and related methods |
WO2002101041A1 (fr) * | 2001-06-12 | 2002-12-19 | Takara Bio Inc. | Procede d'amplification de l'acide nucleique et procede de detection du polymorphisme des nucleotides a l'aide d'un analogue de nucleotide |
US20030032028A1 (en) * | 2001-06-12 | 2003-02-13 | Gayle Dace | In vitro capture of nucleic acids via modified oligonucleotides and magnetic beads |
GB0114719D0 (en) * | 2001-06-15 | 2001-08-08 | Glaxo Group Ltd | Compound |
CA2633171C (en) | 2001-06-20 | 2012-11-20 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
AU2002315393A1 (en) | 2001-06-21 | 2003-01-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
US7153954B2 (en) | 2001-07-12 | 2006-12-26 | Santaris Pharma A/S | Method for preparation of LNA phosphoramidites |
IL159756A0 (en) | 2001-07-12 | 2004-06-20 | Univ Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
US6822088B2 (en) | 2001-07-17 | 2004-11-23 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides on solid support |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
US7060809B2 (en) | 2001-09-04 | 2006-06-13 | Exiqon A/S | LNA compositions and uses thereof |
DE60238143D1 (de) | 2001-09-18 | 2010-12-09 | Genentech Inc | Zusammensetzungen und verfahren für die diagnose von tumoren |
DE60234369D1 (de) | 2001-09-19 | 2009-12-24 | Alexion Pharma Inc | Manipulierte matrizen und ihre verwendung bei der single-primer-amplifikation |
US7414111B2 (en) | 2001-09-19 | 2008-08-19 | Alexion Pharmaceuticals, Inc. | Engineered templates and their use in single primer amplification |
US7468244B2 (en) | 2001-09-27 | 2008-12-23 | University Of Delaware | Polymorphism detection and separation |
EP1446503A2 (en) | 2001-09-27 | 2004-08-18 | University Of Delaware | Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration |
NZ577565A (en) | 2001-10-09 | 2010-10-29 | Isis Pharmaceuticals Inc | Antisense modulation of insulin-like growth factor binding protein 5 expressions |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
WO2003033696A1 (fr) * | 2001-10-18 | 2003-04-24 | Sankyo Company, Limited | Compose antisens vegf |
WO2003039523A2 (en) * | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
JP2005508196A (ja) | 2001-11-07 | 2005-03-31 | アプレラ コーポレイション | 核酸分析の汎用ヌクレオチド |
WO2003045310A2 (en) | 2001-11-21 | 2003-06-05 | Applera Corporation | Digital assay |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
AU2002366391A1 (en) * | 2001-12-19 | 2003-06-30 | Quantibact A/S | A method and a kit for determination of a microbial count |
WO2003057160A2 (en) | 2002-01-02 | 2003-07-17 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
ATE458047T1 (de) | 2002-03-07 | 2010-03-15 | Univ Delaware | Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff |
US7737264B2 (en) | 2002-04-05 | 2010-06-15 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation HIF-1α expression |
MXPA04010092A (es) | 2002-04-16 | 2004-12-13 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
AU2003237249A1 (en) * | 2002-05-24 | 2003-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
WO2003100017A2 (en) * | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
AU2003248708A1 (en) * | 2002-06-17 | 2003-12-31 | Isis Pharmaceuticals, Inc. | Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation |
US7005265B1 (en) | 2002-06-20 | 2006-02-28 | Wenhong Fan | Nonenzymatic catalytic signal amplification for nucleic acid hybridization assays |
US20050053942A1 (en) * | 2002-06-24 | 2005-03-10 | Sakari Kauppinen | Methods and systems for detection and isolation of a nucleotide sequence |
FI20021325A0 (fi) | 2002-07-05 | 2002-07-05 | Valtion Teknillinen | Menetelmä ja reagenssipakkaus yksittäisten polynukleotidien määrän määrittämiseksi |
US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
CN1694959B (zh) | 2002-09-13 | 2013-09-18 | 雷普利瑟公司 | 非序列互补的抗病毒寡核苷酸 |
EP1549767A4 (en) | 2002-09-26 | 2006-06-07 | Amgen Inc | MODULATION OF FORKHEAD BOX O1A GENE EXPRESSION |
US20040219565A1 (en) | 2002-10-21 | 2004-11-04 | Sakari Kauppinen | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
WO2004035819A2 (en) * | 2002-10-21 | 2004-04-29 | Exiqon A/S | Oligonucleotide analogues for detecting and analyzing nucleic acids |
US7696345B2 (en) | 2002-11-05 | 2010-04-13 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
CA2504929C (en) | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US9150606B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
EP2336318B1 (en) | 2002-11-13 | 2013-04-24 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
ES2420914T3 (es) | 2002-11-13 | 2013-08-27 | Genzyme Corporation | Modulación antisentido de la expresión de la apolipoproteína B |
US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
WO2004046160A2 (en) | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
EP2135948B1 (en) | 2002-11-25 | 2014-09-17 | Masafumi Matsuo | ENA nucleic acid drugs modifying splicing in mRNA precursor |
US20040115634A1 (en) | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Modulation of stat 6 expression |
US7713738B2 (en) | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
JP4503590B2 (ja) | 2003-02-10 | 2010-07-14 | サンタリス ファーマ アー/エス | サバイビン発現を調整するためのオリゴマー化合物 |
ES2400033T3 (es) | 2003-02-11 | 2013-04-05 | Antisense Therapeutics Ltd | Modulación de la expresión del receptor del factor de crecimiento I similar a la insulina |
WO2004074503A2 (en) * | 2003-02-21 | 2004-09-02 | Hoser Mark J | Nucleic acid sequencing methods, kits and reagents |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
CA2519860C (en) | 2003-03-21 | 2018-01-16 | Santaris Pharma A/S | Short interfering rna (sirna) analogues |
WO2004096124A2 (en) | 2003-04-01 | 2004-11-11 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
AU2005212433B2 (en) | 2003-05-23 | 2010-12-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA) |
BRPI0410886A (pt) | 2003-06-03 | 2006-07-04 | Isis Pharmaceuticals Inc | composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único |
WO2004111266A1 (en) | 2003-06-17 | 2004-12-23 | Human Genetic Signatures Pty Ltd | Methods for genome amplification |
DK1639130T3 (da) | 2003-06-20 | 2012-07-09 | Exiqon As | Prober, biblioteker og kits til analyse af blandinger af nukleinsyrer og metoder til opbygning af disse |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
JP4731324B2 (ja) | 2003-08-28 | 2011-07-20 | 武 今西 | N−o結合性架橋構造型新規人工核酸 |
CA2537810C (en) | 2003-09-04 | 2012-12-18 | Human Genetic Signatures Pty Ltd | Nucleic acid detection assay |
US20050053981A1 (en) * | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
US7425544B2 (en) | 2003-09-18 | 2008-09-16 | Eli Lilly And Company | Modulation of eIF4E expression |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
US7906639B2 (en) | 2003-11-07 | 2011-03-15 | Sankyo Company, Limited | Oligonucleotides having a 2′-O,4′-C-ethylene nucleotide in the third position of the 3′-end |
WO2005049849A2 (en) | 2003-11-14 | 2005-06-02 | Integrated Dna Technologies, Inc. | Fluorescence quenching azo dyes, their methods of preparation and use |
EP1689432B1 (en) | 2003-11-17 | 2009-12-30 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
DE602004018732D1 (de) | 2003-11-20 | 2009-02-12 | Exiqon As | Löscher-Zusammensetzung mit Anthraquinon |
CN100569945C (zh) | 2003-12-23 | 2009-12-16 | 桑塔里斯制药公司 | 用于调节bcl-2的寡聚化合物 |
WO2005071080A2 (en) | 2004-01-20 | 2005-08-04 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US8790919B2 (en) | 2004-03-15 | 2014-07-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of RNA by RNase H |
US20070265220A1 (en) * | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8192937B2 (en) | 2004-04-07 | 2012-06-05 | Exiqon A/S | Methods for quantification of microRNAs and small interfering RNAs |
WO2005105157A2 (en) | 2004-04-23 | 2005-11-10 | The Trustees Of Columbia University In The City Ofnew York | INHIBITION OF HAIRLESS PROTEIN mRNA |
US8168777B2 (en) | 2004-04-29 | 2012-05-01 | Human Genetic Signatures Pty. Ltd. | Bisulphite reagent treatment of nucleic acid |
US20050287558A1 (en) | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
ATE476439T1 (de) | 2004-09-10 | 2010-08-15 | Human Genetic Signatures Pty | Amplifikationsblocker umfassend interkalierende nukleinsäuren (ina) enthaltend interkalierende pseudonukleotide (ipn) |
CA2581174A1 (en) | 2004-09-16 | 2006-03-30 | Applera Corporation | Fluorescent dye compounds, conjugates and uses thereof |
US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
US20060154888A1 (en) | 2004-11-09 | 2006-07-13 | Santaris Pharma A/S | LNA oligonucleotides and the treatment of cancer |
DE602005022768D1 (de) | 2004-11-09 | 2010-09-16 | Santaris Pharma As | Wirksame lna-oligonukleotide zur inhibierung von hif-1a |
EP1828411B1 (en) | 2004-12-03 | 2012-11-07 | Human Genetic Signatures PTY Ltd | Methods for simplifying microbial nucleic acids by chemical modification of cytosines |
WO2006069584A2 (en) | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
EP2208796B1 (en) | 2005-01-06 | 2014-06-18 | Applied Biosystems, LLC | Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification |
CN101175769A (zh) | 2005-03-10 | 2008-05-07 | 健泰科生物技术公司 | 用于调控血管完整性的方法和组合物 |
US20090264635A1 (en) | 2005-03-25 | 2009-10-22 | Applera Corporation | Methods and compositions for depleting abundant rna transcripts |
EP1866414B9 (en) | 2005-03-31 | 2012-10-03 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
DE602005018840D1 (de) | 2005-04-14 | 2010-02-25 | Applied Biosystems Llc | 3'-modifizierte oligonukleotide mit pseudoisocytosin-nukleobasenderivaten sowie deren anwendungen als primer oder sonden |
US7838502B2 (en) | 2005-05-06 | 2010-11-23 | University Of Massachusetts Medical School | Compositions and methods to modulate H. influenzae pathogenesis |
AU2006246116A1 (en) | 2005-05-11 | 2006-11-16 | Aarhus Universitet | Method for diagnosis and treatment of a mental disease |
AU2006247739A1 (en) | 2005-05-11 | 2006-11-23 | Vector Tobacco Inc. | Reduced risk tobacco products and methods of making same |
WO2006127507A2 (en) * | 2005-05-20 | 2006-11-30 | Integrated Dna Technologies, Inc. | Compounds and methods for labeling oligonucleotides |
ES2436760T3 (es) * | 2005-05-25 | 2014-01-07 | Tina Holding Aps | Formación estable y selectiva de triples hélices y dobles hélices de tipo Hoogsteen empleando ácidos nucleicos intercalantes con torsión (TINA) y procedimiento para la preparación de TINA |
JP2008541705A (ja) | 2005-05-26 | 2008-11-27 | ヒューマン ジェネティック シグネチャーズ ピーティーワイ リミテッド | 非標準塩基を含むプライマーを使用する等温鎖置換増幅 |
EP1891141B1 (en) | 2005-05-31 | 2016-11-16 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
EP1910549B1 (en) | 2005-07-15 | 2010-11-24 | Life Technologies Corporation | Analyzing messenger rna and micro rna in the same reaction mixture |
EP2405024A1 (en) | 2005-07-15 | 2012-01-11 | Life Technologies Corporation | Hot start reverse transcription by primer design |
JP2009504168A (ja) | 2005-08-17 | 2009-02-05 | メディクシス エス.エー. | Ck19発現を確認する組成物及び方法 |
WO2007027775A2 (en) | 2005-08-29 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Methods for use in modulating mir-122a |
US20090203893A1 (en) | 2005-08-29 | 2009-08-13 | Regulus Therapeutics, Llc | Antisense compounds having enhanced anti-microrna activity |
WO2007026823A1 (ja) * | 2005-08-31 | 2007-03-08 | Osaka University | 人工核酸プローブを用いた三重鎖核酸形成を基盤とした標的核酸の検出 |
US20070059713A1 (en) | 2005-09-09 | 2007-03-15 | Lee Jun E | SSB-DNA polymerase fusion proteins |
ATE531820T1 (de) | 2005-09-14 | 2011-11-15 | Human Genetic Signatures Pty | Gesundheitszustandstest |
WO2007041201A2 (en) | 2005-10-03 | 2007-04-12 | Applera Corporation | Compositions, methods, and kits for amplifying nucleic acids |
WO2007064945A2 (en) | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
EP1957645B1 (en) | 2005-12-06 | 2010-11-17 | Ambion Inc. | Reverse transcription primers and methods of design |
WO2007073149A1 (en) | 2005-12-22 | 2007-06-28 | Keygene N.V. | Alternative nucleotides for improved targeted nucleotide exchange |
JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードrna転写物 |
JP5829373B2 (ja) | 2006-01-27 | 2015-12-09 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Nogoレセプターアンタゴニスト |
ES2516815T3 (es) * | 2006-01-27 | 2014-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6 |
EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
WO2007106690A2 (en) | 2006-03-15 | 2007-09-20 | Siemens Healthcare Diagnostics Inc. | Degenerate nucleobase analogs |
WO2007104318A2 (en) | 2006-03-16 | 2007-09-20 | Pentabase Aps | Oligonucleotides comprising signalling pairs and hydrophobic nucleotides, stemless beacons, for detection of nucleic acids, methylation status and mutants of nucleic acids |
WO2007107162A2 (en) | 2006-03-23 | 2007-09-27 | Santaris Pharma A/S | Small internally segmented interfering rna |
EP2194129A3 (en) | 2006-04-03 | 2012-12-26 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides |
SG170773A1 (en) | 2006-04-03 | 2011-05-30 | Santaris Pharma As | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
JP2009535642A (ja) | 2006-05-03 | 2009-10-01 | ゲイシンガー クリニック | 非アルコール性脂肪性肝炎(nash)を診断及び予測する方法 |
EP2505650A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of PCSK9 |
US8586554B2 (en) | 2006-05-05 | 2013-11-19 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of PTP1B |
DK2066684T3 (da) | 2006-05-11 | 2012-10-22 | Isis Pharmaceuticals Inc | 5´-Modificerede bicycliske nukleinsyreanaloge |
US9506056B2 (en) | 2006-06-08 | 2016-11-29 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
CA2659301A1 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
CN101558167A (zh) | 2006-08-01 | 2009-10-14 | 应用生物系统有限公司 | 分析物和核酸的检测 |
US7947487B2 (en) | 2006-10-05 | 2011-05-24 | Massachusetts Institute Of Technology | Multifunctional encoded particles for high-throughput analysis |
ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
EP2090665A2 (en) | 2006-10-20 | 2009-08-19 | Exiqon A/S | Novel human microRNAs associated with cancer |
WO2008052774A2 (en) | 2006-10-31 | 2008-05-08 | Noxxon Pharma Ag | Methods for detection of a single- or double-stranded nucleic acid molecule |
WO2008060613A1 (en) | 2006-11-15 | 2008-05-22 | The J. David Gladstone Institutes | Methods and compositions for reducing amyloid beta levels |
US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
US8084437B2 (en) | 2006-11-27 | 2011-12-27 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
US8293684B2 (en) | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
EP2118118B1 (en) * | 2007-01-19 | 2017-09-27 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
KR101488800B1 (ko) | 2007-02-09 | 2015-02-04 | 노오쓰웨스턴 유니버시티 | 세포내 타겟 검출용 입자 |
JP2010521193A (ja) | 2007-03-22 | 2010-06-24 | サンタリス ファーマ アー/エス | Apo−b100発現の阻害のためのrnaアンタゴニスト化合物 |
DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
EP2137311A1 (en) | 2007-03-24 | 2009-12-30 | Genzyme Corporation | Administering antisense oligonucleotides complementary to human apolipoprotein b |
US8999634B2 (en) | 2007-04-27 | 2015-04-07 | Quest Diagnostics Investments Incorporated | Nucleic acid detection combining amplification with fragmentation |
CA2687291A1 (en) | 2007-05-16 | 2008-11-20 | Ktb Tumorforschungsgesellschaft Mbh | Low-viscous anthracycline formulation |
AU2008260277C1 (en) * | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
US9598724B2 (en) | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
US7807372B2 (en) | 2007-06-04 | 2010-10-05 | Northwestern University | Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay |
WO2008153933A2 (en) | 2007-06-06 | 2008-12-18 | Avi Biopharma, Inc. | Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease |
EP2176280B2 (en) † | 2007-07-05 | 2015-06-24 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
ES2547053T3 (es) | 2007-08-01 | 2015-10-01 | Dana Farber Cancer Institute | Enriquecimiento de una secuencia diana |
US8088904B2 (en) | 2007-08-15 | 2012-01-03 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
WO2009027978A1 (en) | 2007-08-30 | 2009-03-05 | Hadasit Medical Research Services & Development Ltd. | NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS |
CN101849008A (zh) | 2007-09-19 | 2010-09-29 | 应用生物系统有限公司 | 用于减少RNAi中的脱靶表型效应的siRNA的不依赖于序列的修饰形式和其稳定形式 |
EP2205741A2 (en) | 2007-10-02 | 2010-07-14 | Amgen Inc. | Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof |
JP5646997B2 (ja) | 2007-10-03 | 2014-12-24 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | 新規siRNA構造 |
DK2205737T3 (da) | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Mikromirer |
EP2212437A4 (en) | 2007-11-07 | 2011-09-28 | Univ British Columbia | MICROFLUIDIC DEVICE AND METHOD OF USING THE DEVICE |
JP2011502515A (ja) | 2007-11-09 | 2011-01-27 | アイシス ファーマシューティカルズ インコーポレイティッド | 第9因子発現の調節 |
BRPI0820391A2 (pt) | 2007-11-09 | 2015-05-19 | Isis Pharmaceutical Inc | Composto, composição e métodos de modulação da expressão do fator 7 |
US8017338B2 (en) | 2007-11-20 | 2011-09-13 | Life Technologies Corporation | Reversible di-nucleotide terminator sequencing |
EP2215250B1 (en) | 2007-11-27 | 2013-02-27 | Human Genetic Signatures Pty Ltd | Enzymes for amplification and copying bisulphite modified nucleic acids |
EP4053546A1 (en) | 2007-12-06 | 2022-09-07 | Genalyte, Inc. | Device and method for performing label-free monitoring of processes. |
CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
US8227431B2 (en) | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
WO2009117589A1 (en) | 2008-03-21 | 2009-09-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising tricyclic nucleosides and methods for their use |
BRPI0911332A2 (pt) | 2008-04-04 | 2019-09-24 | Calando Pharmaceuticals Inc | composições e uso de inibidores de epas1 |
WO2009124238A1 (en) | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
WO2009124295A2 (en) | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
EP2285385A4 (en) | 2008-04-15 | 2013-01-16 | Quark Pharmaceuticals Inc | COMPOUNDS BASED ON RNSI TO INHIBIT NRF2 |
JP5685182B2 (ja) | 2008-04-18 | 2015-03-18 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 初発自己免疫性糖尿病を予防するため、および/または逆転させるためのマイクロスフェアに基づく組成物 |
EP2294181A4 (en) | 2008-05-22 | 2013-04-24 | Isis Pharmaceuticals Inc | MODULATION OF SMRT EXPRESSION |
US8541388B2 (en) | 2008-05-22 | 2013-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating expression of RBP4 |
EP3733871A1 (en) | 2008-05-27 | 2020-11-04 | Dako Denmark A/S | Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers |
EP2297322A1 (en) | 2008-06-04 | 2011-03-23 | The Board of Regents of The University of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
WO2009147684A2 (en) | 2008-06-06 | 2009-12-10 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
AU2009276763B2 (en) | 2008-07-29 | 2015-07-16 | The Board Of Regents Of The University Of Texas Sytem | Selective inhibition of polyglutamine protein expression |
JP5272230B2 (ja) * | 2008-07-30 | 2013-08-28 | 日鉄住金環境株式会社 | ユニバーサルな核酸プローブセットおよびその使用方法 |
WO2010012667A1 (en) | 2008-08-01 | 2010-02-04 | Santaris Pharma A/S | Micro-rna mediated modulation of colony stimulating factors |
WO2010021344A1 (ja) * | 2008-08-22 | 2010-02-25 | 独立行政法人科学技術振興機構 | 新規核酸誘導体およびそれを用いたヌクレアーゼ耐性核酸の調製方法 |
AU2009275387B2 (en) | 2008-08-25 | 2010-07-08 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
EP2334319B1 (en) | 2008-08-25 | 2017-12-06 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to ctgf |
WO2010036696A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acid analogs |
PL2379084T3 (pl) | 2008-10-15 | 2018-04-30 | Ionis Pharmaceuticals, Inc. | Modulowanie ekspresji czynnika XI |
EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
US20120059045A1 (en) | 2008-10-24 | 2012-03-08 | Isis Pharmaceuticals, Inc. | Methods of using oligomeric compounds comprising 2'-substituted nucleosides |
WO2010062627A2 (en) | 2008-10-27 | 2010-06-03 | Genalyte Inc. | Biosensors based on optical probing and sensing |
DK2365803T3 (en) | 2008-11-24 | 2018-01-22 | Univ Northwestern | POLYVALENT RNA NANOPARTICLE COMPOSITIONS |
CN102317458B (zh) | 2008-12-04 | 2018-01-02 | 库尔纳公司 | 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗 |
WO2010065787A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
US8927511B2 (en) | 2008-12-04 | 2015-01-06 | Curna, Inc. | Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF |
WO2010080452A2 (en) | 2008-12-18 | 2010-07-15 | Quark Pharmaceuticals, Inc. | siRNA COMPOUNDS AND METHODS OF USE THEREOF |
JP2012513199A (ja) | 2008-12-22 | 2012-06-14 | キージーン・エン・フェー | 植物プロトプラストにおける標的化遺伝子改変の効率を増大させるための二本鎖rnaの使用 |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
US8680254B2 (en) | 2009-01-14 | 2014-03-25 | Philadelphia Health & Education Corporation | Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease |
US9096895B2 (en) | 2009-02-02 | 2015-08-04 | Exiqon A/S | Method for quantification of small RNA species |
US8536320B2 (en) | 2009-02-06 | 2013-09-17 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
WO2010091308A2 (en) | 2009-02-06 | 2010-08-12 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
JP5766126B2 (ja) | 2009-02-12 | 2015-08-19 | クルナ・インコーポレーテッド | 脳由来神経栄養因子(bdnf)関連疾病の、bdnfに対する天然アンチセンス転写物の抑制による治療 |
WO2010097656A1 (en) | 2009-02-26 | 2010-09-02 | Dako Denmark A/S | Compositions and methods for performing a stringent wash step in hybridization applications |
EP2408796B1 (en) | 2009-03-16 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III |
CN102482677B (zh) | 2009-03-16 | 2017-10-17 | 库尔纳公司 | 通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病 |
CN102549159B (zh) | 2009-03-17 | 2016-08-10 | 库尔纳公司 | 通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病 |
US20120088814A1 (en) | 2009-03-31 | 2012-04-12 | Isis Pharmaceuticals, Inc. | Methods of modulating an immune response to a viral infection |
CA2757694C (en) | 2009-04-15 | 2020-10-06 | Northwestern University | Delivery of oligonucleotide-functionalized nanoparticles |
EP3248618A1 (en) | 2009-04-22 | 2017-11-29 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
EP2421972A2 (en) | 2009-04-24 | 2012-02-29 | The Board of Regents of The University of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions |
EP2421970B1 (en) | 2009-04-24 | 2016-09-07 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
ES2609655T3 (es) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP |
WO2010129799A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
WO2010129861A2 (en) | 2009-05-08 | 2010-11-11 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
EP2432881B1 (en) | 2009-05-18 | 2017-11-15 | CuRNA, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
EP2432796B1 (en) | 2009-05-21 | 2016-08-17 | Siemens Healthcare Diagnostics Inc. | Universal tags with non-natural nucleobases |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
ES2618576T3 (es) | 2009-05-28 | 2017-06-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico |
US8637482B2 (en) | 2009-06-08 | 2014-01-28 | Quark Pharmaceuticals, Inc. | Methods for treating chronic kidney disease |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
JP6128846B2 (ja) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療 |
WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
JP2011024434A (ja) | 2009-07-22 | 2011-02-10 | Galaxy Pharma Inc | オリゴヌクレオチドのスクリーニング方法及びオリゴヌクレオチドライブラリー |
CA2768947C (en) | 2009-07-24 | 2018-06-19 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
WO2011012136A1 (en) | 2009-07-28 | 2011-02-03 | Exiqon A/S | A method for classifying a human cell sample as cancerous |
CA2769665A1 (en) | 2009-08-05 | 2011-02-10 | Opko Curna, Llc | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
ES2599986T3 (es) | 2009-08-11 | 2017-02-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ) |
EP2982755B1 (en) | 2009-08-21 | 2020-10-07 | CuRNA, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
KR101892760B1 (ko) | 2009-08-25 | 2018-08-28 | 큐알엔에이, 인크. | IQGAP에 대한 천연 안티센스 전사체의 억제에 의한 GTPase 활성화 단백질을 함유하는 IQ 모티프(IQGAP)와 관련된 질환의 치료 |
AU2010289400B2 (en) | 2009-09-02 | 2014-10-23 | Curis, Inc. | Mutant smoothened and methods of using the same |
EP3626823A1 (en) | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
CA2775111C (en) | 2009-09-25 | 2019-12-31 | Opko Curna, Llc | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
EP2957641B1 (en) | 2009-10-15 | 2017-05-17 | Ibis Biosciences, Inc. | Multiple displacement amplification |
CA2778442A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
JP6147502B2 (ja) | 2009-10-27 | 2017-06-14 | スウィフト バイオサイエンシーズ, インコーポレイテッド | ポリヌクレオチドプライマー及びプローブ |
US9376690B2 (en) | 2009-10-30 | 2016-06-28 | Northwestern University | Templated nanoconjugates |
WO2011053994A1 (en) | 2009-11-02 | 2011-05-05 | Alnylam Pharmaceuticals, Inc. | Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter |
KR20120102674A (ko) | 2009-11-03 | 2012-09-18 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 중합체 분석물을 검출하는 다용도의 가시적인 방법 |
CA2781469A1 (en) | 2009-11-23 | 2011-05-26 | Swift Biosciences, Inc. | Devices to extend single stranded target molecules |
CN102741294A (zh) | 2009-11-30 | 2012-10-17 | 霍夫曼-拉罗奇有限公司 | 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体 |
CA2781907C (en) | 2009-12-02 | 2019-07-16 | Dako Denmark A/S | Compositions and methods for performing hybridizations with no denaturation |
EP2510098B1 (en) | 2009-12-09 | 2015-02-11 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
KR101718534B1 (ko) | 2009-12-09 | 2017-03-22 | 닛토덴코 가부시키가이샤 | Hsp47 발현의 조절 |
NO2513310T3 (es) | 2009-12-16 | 2018-03-31 | ||
CN102869776B (zh) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病 |
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
CA2785173A1 (en) | 2009-12-29 | 2011-07-28 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
KR101853508B1 (ko) | 2009-12-29 | 2018-06-20 | 큐알엔에이, 인크. | 종양 단백질 63 (p63)에 대한 천연 안티센스 전사체의 억제에 의한 p63에 관련된 질환의 치료 |
ES2677044T3 (es) | 2009-12-31 | 2018-07-27 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el sustrato 2 del receptor de insulina (IRS2) mediante inhibición de transcrito antisentido natural para el IRS2 y factor de transcripción E3 (TFE3) |
US8946181B2 (en) | 2010-01-04 | 2015-02-03 | Curna, Inc. | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 |
RU2612161C2 (ru) | 2010-01-06 | 2017-03-02 | Курна, Инк. | Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы |
WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
ES2677969T3 (es) | 2010-01-08 | 2018-08-07 | Ionis Pharmaceuticals, Inc. | Modulación de la expresión tipo angiopoyetina 3 |
WO2011085102A1 (en) | 2010-01-11 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
WO2011085347A2 (en) | 2010-01-11 | 2011-07-14 | Opko Curna, Llc | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
CN102782135A (zh) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | 通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病 |
US9574191B2 (en) | 2010-02-03 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
JP6006120B2 (ja) | 2010-02-08 | 2016-10-12 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 対立遺伝子多様体の選択的低減 |
JP6018506B2 (ja) | 2010-02-08 | 2016-11-02 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 対立遺伝子多様体の選択的低減 |
CA2790506A1 (en) | 2010-02-22 | 2011-08-25 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
PE20130214A1 (es) | 2010-02-23 | 2013-03-11 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
WO2011108930A1 (en) | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
US8623603B2 (en) | 2010-03-08 | 2014-01-07 | Dana-Farber Cancer Institute, Inc. | Full cold-PCR enrichment with reference blocking sequence |
WO2011113054A2 (en) | 2010-03-12 | 2011-09-15 | Aurasense Llc | Crosslinked polynucleotide structure |
WO2011115817A1 (en) | 2010-03-16 | 2011-09-22 | Isis Pharmaceuticals, Inc. | Methods of preparing 2'-o-substituted purine nucleosides |
WO2011115818A1 (en) | 2010-03-17 | 2011-09-22 | Isis Pharmaceuticals, Inc. | 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
US20120108799A1 (en) | 2010-09-07 | 2012-05-03 | Integrated Dna Technologies, Inc. | Modifications for Antisense Compounds |
EP2553123B1 (en) | 2010-03-26 | 2016-08-24 | Integrated DNA Technologies, Inc. | Methods for enhancing nucleic acid hybridization |
US9506057B2 (en) | 2010-03-26 | 2016-11-29 | Integrated Dna Technologies, Inc. | Modifications for antisense compounds |
WO2011120046A2 (en) | 2010-03-26 | 2011-09-29 | Swift Biosciences, Inc. | Methods and compositions for isolating polynucleotides |
CN102869777B (zh) | 2010-04-02 | 2018-11-02 | 库尔纳公司 | 通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病 |
TWI644675B (zh) | 2010-04-09 | 2018-12-21 | 可娜公司 | 藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病 |
US20110269194A1 (en) | 2010-04-20 | 2011-11-03 | Swift Biosciences, Inc. | Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment |
WO2011139695A2 (en) | 2010-04-28 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom |
EP3173419A1 (en) | 2010-04-28 | 2017-05-31 | Ionis Pharmaceuticals, Inc. | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom |
US9127033B2 (en) | 2010-04-28 | 2015-09-08 | Isis Pharmaceuticals, Inc. | 5′ modified nucleosides and oligomeric compounds prepared therefrom |
US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
MX343559B (es) | 2010-04-29 | 2016-11-10 | Ionis Pharmaceuticals Inc | Modulacion de la expresion de transtiretina. |
ES2465948T3 (es) | 2010-04-30 | 2014-06-09 | Exiqon A/S | Procedimiento de hibridación in situ y tampón |
CN107988228B (zh) | 2010-05-03 | 2022-01-25 | 库尔纳公司 | 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病 |
MX342239B (es) | 2010-05-03 | 2016-09-21 | Genentech Inc * | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
DK2576784T3 (en) | 2010-05-26 | 2018-02-26 | Curna Inc | TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA |
US20130203045A1 (en) | 2010-05-26 | 2013-08-08 | University Of Virginia Patent Foundation | Method for detecting nucleic acids based on aggregate formation |
DK2576783T3 (en) | 2010-05-26 | 2018-03-12 | Curna Inc | TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1 |
WO2011156278A1 (en) | 2010-06-07 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
CA2802049C (en) | 2010-06-07 | 2018-07-10 | Firefly Bioworks, Inc. | Scanning multifunctional particles |
WO2011156202A1 (en) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
US9518259B2 (en) | 2010-06-15 | 2016-12-13 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating interaction between proteins and target nucleic acids |
CA2803882C (en) | 2010-06-23 | 2022-10-18 | Opko Curna, Llc | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
CN102959091A (zh) | 2010-06-30 | 2013-03-06 | 三菱化学美迪恩斯株式会社 | 高灵敏度的突变基因检测方法 |
NZ719520A (en) | 2010-07-06 | 2017-07-28 | Int Tech Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
NO2593547T3 (es) | 2010-07-14 | 2018-04-14 | ||
ES2655500T3 (es) | 2010-07-16 | 2018-02-20 | Tocagen Inc. | Detección de retrovirus |
US20130237585A1 (en) | 2010-07-19 | 2013-09-12 | University Of Rochester | Modulation of dystrophia myotonica-protein kinase (dmpk) expression |
GB201012418D0 (en) | 2010-07-23 | 2010-09-08 | Santaris Pharma As | Process |
EP3372684B1 (en) | 2010-08-24 | 2020-10-07 | Sirna Therapeutics, Inc. | Single-stranded rnai agents containing an internal, non-nucleic acid spacer |
US8877731B2 (en) | 2010-09-22 | 2014-11-04 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
RU2624048C2 (ru) | 2010-10-06 | 2017-06-30 | Курна, Инк. | Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4 |
US8648053B2 (en) | 2010-10-20 | 2014-02-11 | Rosalind Franklin University Of Medicine And Science | Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome |
JP6049623B2 (ja) | 2010-10-22 | 2016-12-21 | カッパーアールエヌエー,インコーポレイテッド | α‐L‐イズロニダーゼ(IDUA)への天然アンチセンス転写物の阻害によるIDUA関連疾患の治療 |
EP3327125B1 (en) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
WO2012061778A2 (en) | 2010-11-05 | 2012-05-10 | Genalyte, Inc. | Optical analyte detection systems and methods of use |
US9150864B2 (en) | 2010-11-08 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
CA3077910A1 (en) | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
JP6071893B2 (ja) | 2010-11-23 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療 |
JP5947309B2 (ja) | 2010-12-02 | 2016-07-06 | キージーン・エン・フェー | オリゴヌクレオチドを用いたdnaの標的改変 |
DK2857512T3 (en) | 2010-12-02 | 2016-10-03 | Keygene Nv | Targeted DNA change |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
MX352460B (es) | 2011-01-11 | 2017-11-24 | Seegene Inc | Detección de secuencias de ácido nucleico objetivo mediante ensayo de escisión y extensión del pto. |
MX365647B (es) | 2011-02-02 | 2019-06-10 | Excaliard Pharmaceuticals Inc | El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas. |
EP2670404B1 (en) | 2011-02-02 | 2018-08-29 | The Trustees of Princeton University | Sirtuin modulators as virus production modulators |
EP3067421B1 (en) | 2011-02-08 | 2018-10-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
US20140044644A1 (en) | 2011-02-21 | 2014-02-13 | University Of Zurich | Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders |
CN103562387A (zh) | 2011-03-03 | 2014-02-05 | 夸克医药公司 | Toll样受体途径的寡核苷酸调剂 |
JP6000287B2 (ja) | 2011-03-03 | 2016-09-28 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | 肺疾患および損傷を治療するための組成物および方法 |
US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
EP2495336B8 (en) | 2011-03-04 | 2014-07-23 | Roche Diagnostics GmbH | A new type of universal probes for the detection of genomic variants |
CN103534358B (zh) | 2011-03-29 | 2015-03-25 | Seegene株式会社 | 基于pto切割以及延伸-依赖性切割的靶核酸序列的检测 |
US11130992B2 (en) | 2011-03-31 | 2021-09-28 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to enable multiplex COLD-PCR |
SI2697243T1 (sl) | 2011-04-01 | 2019-05-31 | Ionis Pharmaceuticals, Inc. | Modulacija izražanja pretvornika signala in aktivatorja transkripcije 3 (STAT3) |
EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
CN105886506A (zh) | 2011-04-13 | 2016-08-24 | Isis制药公司 | Ptp1b 表达的反义调节 |
CN111172162A (zh) | 2011-04-21 | 2020-05-19 | 葛兰素史克公司 | 乙型肝炎病毒(hbv)表达的调节 |
WO2012149154A1 (en) | 2011-04-26 | 2012-11-01 | Swift Biosciences, Inc. | Polynucleotide primers and probes |
BR112013027479A8 (pt) | 2011-04-27 | 2017-10-03 | Isis Pharmaceuticals Inc | Uso de um composto compreendendo um oligonucleotídeo modificado dirigido a apociii |
WO2012149339A2 (en) | 2011-04-29 | 2012-11-01 | Sequenom, Inc. | Quantification of a minority nucleic acid species |
WO2012151289A2 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system to detect aggregate formation on a substrate |
WO2012151324A1 (en) | 2011-05-02 | 2012-11-08 | Isis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with usher syndrome |
WO2012151268A1 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system for high throughput optical and label free detection of analytes |
MX342067B (es) | 2011-05-04 | 2016-09-09 | Seegene Inc | Detección de secuencias de ácido nucleico objetivo por desdoblamiento e hibridización de oligonucleótido de sonda. |
TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Hsp47表現調控強化用類視色素脂質體 |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
WO2012170347A1 (en) | 2011-06-09 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
CN103620036B (zh) | 2011-06-09 | 2016-12-21 | 库尔纳公司 | 通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病 |
US9187749B2 (en) | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
US9315811B2 (en) | 2011-06-10 | 2016-04-19 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
WO2012174476A2 (en) | 2011-06-16 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
CA2840614A1 (en) | 2011-06-29 | 2013-01-03 | Isis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
EP4269584A3 (en) | 2011-08-11 | 2024-03-27 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
EP2751270B1 (en) | 2011-08-29 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
WO2013033223A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
US9650421B2 (en) | 2011-09-02 | 2017-05-16 | Northwestern University | Self-assembled nanostructures |
KR101991980B1 (ko) | 2011-09-06 | 2019-06-21 | 큐알엔에이, 인크. | 소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료 |
NZ622418A (en) | 2011-09-07 | 2014-12-24 | Human Genetic Signatures Pty | Molecular detection assay |
WO2013040499A1 (en) | 2011-09-14 | 2013-03-21 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
KR101840512B1 (ko) | 2011-09-20 | 2018-03-20 | 아이오니스 파마수티컬즈, 인코포레이티드 | Gcgr 발현의 안티센스 조절 |
US10662465B2 (en) | 2011-09-30 | 2020-05-26 | Agilent Technologies, Inc. | Hybridization compositions and methods using formamide |
EP2768974B1 (en) | 2011-10-21 | 2017-07-19 | Dako Denmark A/S | Hybridization compositions and methods |
WO2013063313A1 (en) | 2011-10-25 | 2013-05-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of gccr expression |
MX356814B (es) | 2011-11-03 | 2018-06-13 | Quark Pharmaceuticals Inc | Métodos y composiciones para neuroprotección. |
EP2776564B1 (en) | 2011-11-07 | 2019-10-02 | Ionis Pharmaceuticals, Inc. | Modulation of tmprss6 expression |
US9243291B1 (en) | 2011-12-01 | 2016-01-26 | Isis Pharmaceuticals, Inc. | Methods of predicting toxicity |
WO2013090457A2 (en) | 2011-12-12 | 2013-06-20 | Oncoimmunin Inc. | In vivo delivery of oligonucleotides |
IN2014CN04590A (es) | 2011-12-16 | 2015-09-18 | Nat Univ Corp Tokyo Med & Dent | |
CA2859729C (en) | 2011-12-22 | 2021-03-09 | Isis Pharmaceuticals, Inc. | Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression |
EP3369818B1 (en) | 2011-12-22 | 2021-06-09 | InteRNA Technologies B.V. | Mirna for treating head and neck cancer |
WO2013096679A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
EP2797948B1 (en) | 2011-12-27 | 2019-02-20 | The J. David Gladstone Institutes | Compositions for use in regulating glucose metabolism |
EP2802674B1 (en) | 2012-01-11 | 2020-12-16 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of ikbkap splicing |
WO2013120003A1 (en) | 2012-02-08 | 2013-08-15 | Isis Pharmaceuticals, Inc. | Modulation of rna by repeat targeting |
WO2013133561A1 (en) | 2012-03-05 | 2013-09-12 | Seegene, Inc. | Detection of nucleotide variation on target nucleic acid sequence by pto cleavage and extension assay |
EP3907506A1 (en) | 2012-03-12 | 2021-11-10 | The Board of Trustees of the University of Illinois | Optical analyte detection systems with magnetic enhancement and methods of their use |
JP6509723B2 (ja) | 2012-03-13 | 2019-05-08 | スウィフト バイオサイエンシーズ, インコーポレイテッド | 核酸ポリメラーゼによる基質ポリヌクレオチドの大きさ制御されたホモポリマーテーリングのための方法および組成物 |
ES2694592T3 (es) | 2012-03-15 | 2018-12-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF |
WO2013142514A1 (en) | 2012-03-19 | 2013-09-26 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
AU2013202595B2 (en) | 2012-03-30 | 2016-04-21 | Biogen Ma Inc. | Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome |
WO2013154799A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
US9914922B2 (en) | 2012-04-20 | 2018-03-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
US9133490B2 (en) | 2012-05-16 | 2015-09-15 | Transgenomic, Inc. | Step-up method for COLD-PCR enrichment |
US9574193B2 (en) | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
US20160002624A1 (en) | 2012-05-17 | 2016-01-07 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
EP2852606B1 (en) | 2012-05-22 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | Modulation of enhancer rna mediated gene expression |
KR20170142997A (ko) | 2012-05-24 | 2017-12-28 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지질단백질 (a) 발현을 조절하는 방법들 및 조성물들 |
US9422323B2 (en) | 2012-05-25 | 2016-08-23 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
TR201806812T4 (tr) | 2012-05-25 | 2018-06-21 | Charpentier Emmanuelle | Rna-yönlendirmeli hedef dna modifikasyonu için ve rna-yönlendirmeli transkripsiyon modifikasyonu için yöntemler ve bileşimler. |
WO2013181666A2 (en) | 2012-06-01 | 2013-12-05 | Isis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
US9828602B2 (en) | 2012-06-01 | 2017-11-28 | Ionis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
CA2877905A1 (en) | 2012-06-25 | 2014-01-03 | Isis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
US9695416B2 (en) | 2012-07-18 | 2017-07-04 | Siemens Healthcare Diagnostics Inc. | Method of normalizing biological samples |
EP2877579B1 (en) | 2012-07-27 | 2019-12-18 | Ionis Pharmaceuticals, Inc. | Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen |
US9403865B2 (en) | 2012-08-15 | 2016-08-02 | Ionis Pharmaceuticals, Inc. | Method of preparing oligomeric compounds using modified capping protocols |
US9556216B2 (en) | 2012-08-31 | 2017-01-31 | Novartis Ag | 2′-Ethynyl nucleoside derivatives for treatment of viral infections |
HUE039676T2 (hu) | 2012-09-06 | 2019-01-28 | Univ Chicago | Antiszensz polinukleotidok exon-ugrás indukálására és eljárások disztrófiák kezelésére |
EP2897633B1 (en) | 2012-09-18 | 2020-01-01 | UTI Limited Partnership | Treatment of pain by inhibition of usp5 de-ubiquitinase |
US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
US9695418B2 (en) | 2012-10-11 | 2017-07-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and uses thereof |
WO2014059364A1 (en) | 2012-10-11 | 2014-04-17 | Isis Pharmaceuticals, Inc. | Methods of treating kennedy's disease |
EP3459549B1 (en) | 2012-10-12 | 2022-04-06 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
ES2762326T5 (es) | 2012-10-15 | 2023-04-27 | Ionis Pharmaceuticals Inc | Métodos para modular la expresión de C9ORF72 |
US10577604B2 (en) | 2012-10-15 | 2020-03-03 | Ionis Pharmaceuticals, Inc. | Methods for monitoring C9ORF72 expression |
EP2906258A4 (en) | 2012-10-15 | 2016-08-10 | Ionis Pharmaceuticals Inc | COMPOSITIONS FOR MODULATING THE EXPRESSION OF C90RF72 |
US9029335B2 (en) | 2012-10-16 | 2015-05-12 | Isis Pharmaceuticals, Inc. | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
NZ706540A (en) | 2012-10-31 | 2018-11-30 | Ionis Pharmaceuticals Inc | Dosage regimens for treatment of cancer |
WO2014071406A1 (en) | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression |
EP2917348A1 (en) | 2012-11-06 | 2015-09-16 | InteRNA Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
CA2889596C (en) | 2012-11-15 | 2022-08-23 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
DK2922955T3 (da) | 2012-11-26 | 2019-05-13 | Roche Innovation Ct Copenhagen As | Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression |
WO2014093537A1 (en) | 2012-12-11 | 2014-06-19 | Isis Pharmaceuticals, Inc. | Competitive modulation of micrornas |
PT2935303T (pt) | 2012-12-21 | 2021-04-30 | Alios Biopharma Inc | 4'-fluoro-nucleósidos, 4'-fluoro-nucleótidos e seus análogos para o tratamento de hcv |
EP2943570B1 (en) | 2013-01-14 | 2018-01-03 | Pierfrancesco Tassone | Inhibitors of mirnas 221 and 222 for anti-tumor activity in multiple myeloma |
US9856474B2 (en) | 2013-01-16 | 2018-01-02 | Iowa State University Research Foundation, Inc. | Deep intronic target for splicing correction on spinal muscular atrophy gene |
WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
SG11201505387PA (en) | 2013-01-30 | 2015-08-28 | Hoffmann La Roche | Lna oligonucleotide carbohydrate conjugates |
WO2014120861A2 (en) | 2013-01-31 | 2014-08-07 | Isis Pharmaceuticals, Inc. | Method of preparing oligomeric compounds using modified coupling protocols |
CA3170716A1 (en) | 2013-02-14 | 2014-08-21 | Ionis Pharmaceuticals, Inc. | Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations |
ES2662825T3 (es) | 2013-02-25 | 2018-04-09 | Seegene, Inc. | Detección de variación de nucleótido en una secuencia de ácidos nucleicos diana |
US10086093B2 (en) | 2013-02-28 | 2018-10-02 | The General Hospital Corporation | miRNA profiling compositions and methods of use |
US10398661B2 (en) | 2013-02-28 | 2019-09-03 | The Board Of Regents Of The University Of Texas System | Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers |
WO2014132671A1 (en) | 2013-03-01 | 2014-09-04 | National University Corporation Tokyo Medical And Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
WO2014142575A1 (en) | 2013-03-13 | 2014-09-18 | Seegene, Inc. | Quantification of target nucleic acid using melting peak analysis |
EP2971098B1 (en) | 2013-03-14 | 2018-11-21 | Translate Bio, Inc. | Quantitative assessment for cap efficiency of messenger rna |
MX2015012621A (es) | 2013-03-14 | 2016-05-31 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de tau. |
CN105051213A (zh) | 2013-03-14 | 2015-11-11 | 夏尔人类遗传性治疗公司 | 信使rna加帽效率的定量评估 |
US9273349B2 (en) | 2013-03-14 | 2016-03-01 | Affymetrix, Inc. | Detection of nucleic acids |
WO2014143637A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The University Of Illinois | Methods and compositions for enhancing immunoassays |
US10590412B2 (en) | 2013-04-19 | 2020-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation nucleic acids through nonsense mediated decay |
SG11201508165VA (en) | 2013-04-29 | 2015-11-27 | Sloan Kettering Inst Cancer | Compositions and methods for altering second messenger signaling |
RU2686080C2 (ru) | 2013-05-01 | 2019-04-24 | Ионис Фармасьютикалз, Инк. | Композиции и способы |
EP3004347B1 (en) | 2013-05-30 | 2018-09-26 | National University Corporation Tokyo Medical and Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
ES2862125T3 (es) | 2013-06-13 | 2021-10-07 | Antisense Therapeutics Ltd | Terapia combinada para acromegalia |
EP3010514B1 (en) | 2013-06-16 | 2021-01-20 | National University Corporation Tokyo Medical and Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
EP3656386A1 (en) | 2013-06-21 | 2020-05-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile |
ES2770667T3 (es) | 2013-06-27 | 2020-07-02 | Roche Innovation Ct Copenhagen As | Oligómeros antisentido y conjugados que se dirigen a PCSK9 |
MX2015017863A (es) | 2013-07-02 | 2016-11-30 | Ionis Pharmaceuticals Inc | Moduladores de receptor de hormona de crecimiento. |
KR101863943B1 (ko) | 2013-07-15 | 2018-06-01 | 주식회사 씨젠 | Pto 절단 및 연장-의존적 고정화 올리고뉴클레오타이드 혼성화를 이용한 타겟 핵산 서열의 검출 |
JP6617702B2 (ja) | 2013-07-15 | 2019-12-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Fty720のアザサイクリック拘束アナログ |
TWI702046B (zh) | 2013-07-19 | 2020-08-21 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
US10435430B2 (en) | 2013-07-31 | 2019-10-08 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
HUE048710T2 (hu) | 2013-08-08 | 2020-08-28 | Scripps Research Inst | Eljárás nukleinsavak in vitro helyspecifikus enzimes jelölésére nem-természetes nukleotidok beépítésével |
TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
ES2790574T3 (es) | 2013-08-28 | 2020-10-28 | Ionis Pharmaceuticals Inc | Modulación de expresión de prekallikrein (PKK) |
EP3603677A1 (en) | 2013-09-13 | 2020-02-05 | Ionis Pharmaceuticals, Inc. | Modulators of complement factor b |
US10077444B2 (en) | 2013-10-02 | 2018-09-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
LT3052628T (lt) | 2013-10-04 | 2020-09-10 | Alnylam Pharmaceuticals, Inc. | Kompozicijos ir būdai alas1 geno raiškai nuslopinti |
EP4166667A3 (en) | 2013-10-11 | 2023-08-02 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
JP6640079B2 (ja) | 2013-10-16 | 2020-02-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 小容積の粒子を調製するためのデバイス及び方法 |
EP3058105B1 (en) | 2013-10-18 | 2019-05-22 | Seegene, Inc. | Detection of target nucleic acid sequence on solid phase by pto cleavage and extension using hcto assay |
WO2015061246A1 (en) | 2013-10-21 | 2015-04-30 | Isis Pharmaceuticals, Inc. | Method for solution phase detritylation of oligomeric compounds |
WO2015066708A1 (en) | 2013-11-04 | 2015-05-07 | Northwestern University | Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna) |
WO2015071474A2 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
WO2015075166A1 (en) | 2013-11-22 | 2015-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of a bacterial infection |
US10182988B2 (en) | 2013-12-03 | 2019-01-22 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
US10385388B2 (en) | 2013-12-06 | 2019-08-20 | Swift Biosciences, Inc. | Cleavable competitor polynucleotides |
EP3798306A1 (en) | 2013-12-12 | 2021-03-31 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
EP3835419A1 (en) | 2013-12-12 | 2021-06-16 | The Regents of The University of California | Methods and compositions for modifying a single stranded target nucleic acid |
EP3770259A1 (en) | 2013-12-24 | 2021-01-27 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
US9765332B2 (en) | 2014-01-29 | 2017-09-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Oligonucleotides and methods for inhibiting or reducing bacterial biofilms |
JP6736467B2 (ja) | 2014-02-04 | 2020-08-05 | ジェネンテック, インコーポレイテッド | 平滑化変異体及びその使用方法 |
KR20230152154A (ko) | 2014-02-11 | 2023-11-02 | 알닐람 파마슈티칼스 인코포레이티드 | 케토헥소키나제(KHK) iRNA 조성물 및 그의 사용 방법 |
EP2907874A1 (en) | 2014-02-14 | 2015-08-19 | Université de Lausanne | MiR-21-3p inhibitors in skin disorders |
US10036019B2 (en) | 2014-03-17 | 2018-07-31 | Ionis Pharmaceuticals, Inc. | Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom |
SG11201607761UA (en) | 2014-03-19 | 2016-10-28 | Ionis Pharmaceuticals Inc | Compositions for modulating ataxin 2 expression |
PT3757214T (pt) | 2014-04-01 | 2022-08-26 | Biogen Ma Inc | Composições para modulação da expressão de sod-1 |
EP3943607A1 (en) | 2014-04-09 | 2022-01-26 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
WO2015164693A1 (en) | 2014-04-24 | 2015-10-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising alpha-beta-constrained nucleic acid |
EP3137476B1 (en) | 2014-04-28 | 2019-10-09 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
MX2016014102A (es) | 2014-05-01 | 2017-05-03 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3. |
WO2015168618A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
KR102366078B1 (ko) | 2014-05-01 | 2022-02-21 | 아이오니스 파마수티컬즈, 인코포레이티드 | Pkk 발현을 조절하는 조성물 및 방법 |
PE20170010A1 (es) | 2014-05-01 | 2017-03-04 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion del factor b del complemento |
EP3137115B1 (en) | 2014-05-01 | 2020-10-14 | Ionis Pharmaceuticals, Inc. | Method for synthesis of reactive conjugate clusters |
TW201607559A (zh) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | 治療serpinc1相關疾患之方法和組成物 |
GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
SG10202104570TA (en) | 2014-05-22 | 2021-06-29 | Alnylam Pharmaceuticals Inc | Angiotensinogen (agt) irna compositions and methods of use thereof |
EP3155100B1 (en) | 2014-06-10 | 2021-12-22 | Erasmus University Medical Center Rotterdam | Antisense oligonucleotides useful in treatment of pompe disease |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法 |
JP6562517B2 (ja) * | 2014-07-31 | 2019-08-21 | 国立大学法人大阪大学 | 架橋型ヌクレオシドおよびヌクレオチド |
CA2958431A1 (en) | 2014-08-19 | 2016-02-25 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
IL234246A0 (en) | 2014-08-21 | 2014-11-30 | Omrix Biopharmaceuticals Ltd | Stabilized thrombin |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
US10731163B2 (en) | 2014-09-02 | 2020-08-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Oligonucleotide targeted to the A20-3′ untranslated region |
EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
EP3194597B1 (en) | 2014-09-18 | 2021-06-30 | The University Of British Columbia | Allele-specific therapy for huntington disease haplotypes |
WO2016054032A1 (en) | 2014-09-29 | 2016-04-07 | The Jackson Laboratory | High efficiency, high throughput generation of genetically modified mammals by electroporation |
WO2016054615A2 (en) | 2014-10-03 | 2016-04-07 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
WO2016061131A1 (en) | 2014-10-14 | 2016-04-21 | The J. David Gladstone Institutes | Compositions and methods for reactivating latent immunodeficiency virus |
WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
EP3904519A1 (en) | 2014-10-30 | 2021-11-03 | Genzyme Corporation | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
SG11201703646SA (en) | 2014-11-10 | 2017-06-29 | Glaxosmithkline Intellectual Property (No 2) Ltd | Combination long acting compositions and methods for hepatitis c |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
MX2017006139A (es) | 2014-11-10 | 2017-11-16 | Glaxosmithkline Intelectual Property (No 2) Ltd | Composiciones farmaceuticas de accion prolongada para hepatitis c. |
WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US10400243B2 (en) | 2014-11-25 | 2019-09-03 | Ionis Pharmaceuticals, Inc. | Modulation of UBE3A-ATS expression |
EP3234141A4 (en) | 2014-12-18 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Reversir tm compounds |
DK3237636T3 (da) | 2014-12-22 | 2021-01-25 | Anapa Biotech As | Dobbelt-quenching analyse til multiplex detektion af målnukleinsyrer |
US9688707B2 (en) | 2014-12-30 | 2017-06-27 | Ionis Pharmaceuticals, Inc. | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom |
CA2975875A1 (en) | 2015-02-04 | 2016-08-11 | Genentech, Inc. | Mutant smoothened and methods of using the same |
CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
US10758558B2 (en) | 2015-02-13 | 2020-09-01 | Translate Bio Ma, Inc. | Hybrid oligonucleotides and uses thereof |
WO2016138353A1 (en) | 2015-02-26 | 2016-09-01 | Ionis Pharmaceuticals, Inc. | Allele specific modulators of p23h rhodopsin |
EP4056703A1 (en) | 2015-03-03 | 2022-09-14 | Ionis Pharmaceuticals, Inc. | Methods for modulating mecp2 expression |
WO2016141236A1 (en) | 2015-03-03 | 2016-09-09 | Ionis Pharmaceuticals, Inc. | Compositions for modulating mecp2 expression |
US10415038B2 (en) | 2015-04-03 | 2019-09-17 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating TMPRSS6 expression |
RS61349B1 (sr) | 2015-04-08 | 2021-02-26 | Univ Chicago | Kompozicije i postupci za korigovanje udno-pojasne mišične distrofije tipa 2c upotrebom preskakanja egzona |
US10745702B2 (en) | 2015-04-08 | 2020-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
AU2016247922B2 (en) | 2015-04-13 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
SG10202001856WA (en) | 2015-04-16 | 2020-04-29 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
WO2016196655A1 (en) | 2015-06-03 | 2016-12-08 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
WO2017011286A1 (en) | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
CA3205381A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
WO2017023861A1 (en) | 2015-08-03 | 2017-02-09 | The Regents Of The University Of California | Compositions and methods for modulating abhd2 activity |
KR20180043819A (ko) | 2015-08-24 | 2018-04-30 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | Lna-g 방법 |
SG10202007937SA (en) | 2015-09-02 | 2020-09-29 | Alnylam Pharmaceuticals Inc | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
DK3350347T3 (da) | 2015-09-14 | 2021-04-19 | Pentabase Aps | Fremgangsmåder og materialer til detektion af mutationer |
EP3350328A1 (en) | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
TW201718857A (zh) | 2015-09-14 | 2017-06-01 | 艾爾妮蘭製藥公司 | 用於抑制alas1基因表現之組合物及方法 |
TW201718618A (zh) * | 2015-09-18 | 2017-06-01 | 田邊三菱製藥股份有限公司 | 架橋型核酸GuNA,其製造方法,及中間體化合物 |
MX2018003685A (es) | 2015-09-24 | 2018-08-15 | Univ California | Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento. |
US20190048340A1 (en) | 2015-09-24 | 2019-02-14 | Crispr Therapeutics Ag | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
US10533175B2 (en) | 2015-09-25 | 2020-01-14 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating Ataxin 3 expression |
CN113817735A (zh) | 2015-10-08 | 2021-12-21 | Ionis制药公司 | 用于调节血管紧张素原表达的化合物和方法 |
SG11201802870RA (en) | 2015-10-09 | 2018-05-30 | Univ Southampton | Modulation of gene expression and screening for deregulated protein expression |
CA3001014A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
DK3362461T3 (da) | 2015-10-16 | 2022-05-09 | Modernatx Inc | Mrna-cap-analoger med modificeret phosphatbinding |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
EP3183347A4 (en) | 2015-10-17 | 2018-04-18 | Lifesplice Pharma LLC | Splice modulating oligonucleotides and methods of use thereof |
WO2017068087A1 (en) | 2015-10-22 | 2017-04-27 | Roche Innovation Center Copenhagen A/S | Oligonucleotide detection method |
JP7023842B2 (ja) | 2015-10-29 | 2022-02-22 | テンプル ユニヴァーシティ - オブ ザ コモンウェルス システム オブ ハイアー エデュケーション | Dnaポリメラーゼシータによる核酸の3’末端の修飾 |
US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
US20190046555A1 (en) | 2015-11-06 | 2019-02-14 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds for use in therapy |
CN108348478A (zh) | 2015-11-06 | 2018-07-31 | Ionis 制药公司 | 调节载脂蛋白(a)表达 |
CR20200118A (es) | 2015-11-12 | 2021-04-21 | Hoffmann La Roche | OLIGONUCLEÍTIDOS PARA INDUCIR LA EXPRESIÓN PATERNA DE UBE3A (Divisional 2018-0264) |
AU2016359629B2 (en) | 2015-11-23 | 2023-03-09 | Ranjan BATRA | Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9 |
US10993995B2 (en) | 2015-12-07 | 2021-05-04 | Erasmus University Medical Center Rotterdam | Enzymatic replacement therapy and antisense therapy for pompe disease |
KR20230119027A (ko) | 2015-12-07 | 2023-08-14 | 젠자임 코포레이션 | Serpinc1-연관 장애의 치료를 위한 방법 및 조성물 |
WO2017098468A1 (en) | 2015-12-09 | 2017-06-15 | Novartis Ag | Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry |
EP3387129A1 (en) | 2015-12-10 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
WO2017106377A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
JOP20200228A1 (ar) | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
US10907160B2 (en) | 2016-01-05 | 2021-02-02 | Ionis Pharmaceuticals, Inc. | Methods for reducing LRRK2 expression |
JP7349788B2 (ja) | 2016-01-06 | 2023-09-25 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 分岐ミキサー並びにその使用及び製造方法 |
EP3402327A1 (en) | 2016-01-15 | 2018-11-21 | The Jackson Laboratory | Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein |
WO2017136558A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
JP6853537B2 (ja) | 2016-02-17 | 2021-03-31 | 国立大学法人東京工業大学 | 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド |
US11008608B2 (en) | 2016-02-26 | 2021-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | Multiplexed single molecule RNA visualization with a two-probe proximity ligation system |
WO2017156242A1 (en) | 2016-03-09 | 2017-09-14 | Ionis Pharmaceuticals, Inc. | Methods and compositions for inhibiting pmp22 expression |
KR102417646B1 (ko) | 2016-03-14 | 2022-07-07 | 에프. 호프만-라 로슈 아게 | Pd-l1 발현의 감소를 위한 올리고뉴클레오티드 |
WO2017161172A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Methods of modulating keap1 |
EP3443094B1 (en) | 2016-04-13 | 2022-10-19 | Ionis Pharmaceuticals, Inc. | Methods for reducing c9orf72 expression |
EP3442983A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE |
MA45295A (fr) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser |
WO2017188898A1 (en) | 2016-04-29 | 2017-11-02 | Nanyang Technological University | G-quadruplex-containing antisense oligonucleotides |
CA3023764A1 (en) | 2016-06-06 | 2017-12-14 | Arrowhead Pharmaceuticals, Inc. | 5'-cyclo-phosphonate modified nucleotides |
US20190256845A1 (en) | 2016-06-10 | 2019-08-22 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
US11708614B2 (en) | 2016-06-15 | 2023-07-25 | Streck Llc | Assays and methods for determining microbial resistance |
US10337051B2 (en) | 2016-06-16 | 2019-07-02 | The Regents Of The University Of California | Methods and compositions for detecting a target RNA |
MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
HUE060123T2 (hu) | 2016-06-24 | 2023-01-28 | Scripps Research Inst | Új nukleozid-trifoszfát-transzporter és alkalmazásai |
TW201803990A (zh) | 2016-07-01 | 2018-02-01 | 赫孚孟拉羅股份公司 | 用於調節htra1表現之反股寡核苷酸 |
WO2018014041A2 (en) | 2016-07-15 | 2018-01-18 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of smn2 |
WO2018024849A1 (en) | 2016-08-03 | 2018-02-08 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
SG10201607303YA (en) | 2016-09-01 | 2018-04-27 | Agency Science Tech & Res | Antisense oligonucleotides to induce exon skipping |
HUE059718T2 (hu) | 2016-09-02 | 2022-12-28 | Dicerna Pharmaceuticals Inc | 4'-foszfát analógok és azokat tartalmazó oligonukleotidok |
JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
CN109661233A (zh) | 2016-10-06 | 2019-04-19 | Ionis 制药公司 | 缀合低聚化合物的方法 |
WO2018075827A1 (en) | 2016-10-19 | 2018-04-26 | Arcturus Therapeutics, Inc. | Trinucleotide mrna cap analogs |
SG10201609048RA (en) | 2016-10-28 | 2018-05-30 | Agency Science Tech & Res | Antisense oligonucleotides |
JOP20190104A1 (ar) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
WO2018087200A1 (en) | 2016-11-11 | 2018-05-17 | Roche Innovation Center Copenhagen A/S | Therapeutic oligonucleotides capture and detection |
TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
EP3548620A4 (en) | 2016-12-02 | 2020-07-22 | Cold Spring Harbor Laboratory | MODULATION OF THE EXPRESSION OF LNC05 |
US11371090B2 (en) | 2016-12-12 | 2022-06-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for molecular barcoding of DNA molecules prior to mutation enrichment and/or mutation detection |
AU2017376950B2 (en) | 2016-12-16 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions |
CN110199023A (zh) | 2016-12-28 | 2019-09-03 | 第一三共株式会社 | 阿尔波特氏综合症治疗药 |
CN110268060A (zh) | 2017-01-10 | 2019-09-20 | 箭头药业股份有限公司 | α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法 |
US20190345495A1 (en) | 2017-01-13 | 2019-11-14 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating nfkb2 expression |
US20190345496A1 (en) | 2017-01-13 | 2019-11-14 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating relb expression |
US20190367920A1 (en) | 2017-01-13 | 2019-12-05 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating nfkb1 expression |
EP3568477A1 (en) | 2017-01-13 | 2019-11-20 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating rela expression |
EP3568478A1 (en) | 2017-01-13 | 2019-11-20 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating rel expression |
CN110337495B (zh) | 2017-02-06 | 2024-03-29 | 日产化学株式会社 | 单链寡核苷酸 |
WO2018165564A1 (en) | 2017-03-09 | 2018-09-13 | Ionis Pharmaceuticals, Inc. | Morpholino modified oligomeric compounds |
JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
EP3603648A4 (en) | 2017-03-29 | 2020-12-30 | Shionogi & Co., Ltd | COMPLEX OF NUCLEIC ACID MEDICINAL AND MULTI-BRANCHED LIPID |
TWI801377B (zh) | 2017-04-18 | 2023-05-11 | 美商阿尼拉製藥公司 | 治療具有b型肝炎病毒(hbv)感染之個體之方法 |
JP7398279B2 (ja) | 2017-05-10 | 2023-12-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Crispr/cas9核送達による細胞rnaの狙いを定めた編集 |
US20190055564A1 (en) | 2017-06-01 | 2019-02-21 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides for modulating htra1 expression |
EP3599844A4 (en) | 2017-06-07 | 2021-01-13 | University of Massachusetts | ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED PROCESSES |
AU2018300069A1 (en) | 2017-07-11 | 2020-02-27 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
KR20200028997A (ko) | 2017-07-13 | 2020-03-17 | 노오쓰웨스턴 유니버시티 | 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법 |
US11174511B2 (en) | 2017-07-24 | 2021-11-16 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for selecting and amplifying DNA targets in a single reaction mixture |
JP7384033B2 (ja) | 2017-07-26 | 2023-11-21 | 日産化学株式会社 | 一本鎖オリゴヌクレオチド |
US20200181220A1 (en) | 2017-08-03 | 2020-06-11 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
WO2019030313A2 (en) | 2017-08-11 | 2019-02-14 | Roche Innovation Center Copenhagen A/S | OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION |
US20200209228A1 (en) * | 2017-08-18 | 2020-07-02 | European Molecular Biology Laboratory | ENHANCED RNA INTERACTOME CAPTURE (eRIC) |
US11197884B2 (en) | 2017-08-18 | 2021-12-14 | Ionis Pharmaceuticals, Inc. | Modulation of the notch signaling pathway for treatment of respiratory disorders |
WO2019038228A1 (en) | 2017-08-22 | 2019-02-28 | Roche Innovation Center Copenhagen A/S | OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION |
GB2599884B (en) | 2017-08-25 | 2022-08-31 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
KR102380264B1 (ko) | 2017-08-31 | 2022-03-29 | 주식회사 씨젠 | 다이머-형성 프라이머 쌍을 이용한 구성요소의 성능 평가 |
KR102345601B1 (ko) | 2017-09-29 | 2021-12-30 | 주식회사 씨젠 | Pto 절단 및 연장-의존적 연장 분석에 의한 타겟 핵산 서열의 검출 |
EP3694995A1 (en) | 2017-10-13 | 2020-08-19 | Roche Innovation Center Copenhagen A/S | Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides |
KR20200030594A (ko) | 2017-10-16 | 2020-03-20 | 에프. 호프만-라 로슈 아게 | B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자 |
US11261445B2 (en) | 2017-10-17 | 2022-03-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination treatment for cystic fibrosis |
AU2018360697A1 (en) | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
US11497762B2 (en) | 2017-11-03 | 2022-11-15 | Interna Technologies B.V. | MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
US20200385719A1 (en) | 2017-11-16 | 2020-12-10 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
EP3714054A1 (en) | 2017-11-20 | 2020-09-30 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
WO2019111791A1 (ja) * | 2017-12-07 | 2019-06-13 | 第一三共株式会社 | ジストロフィン遺伝子のイントロンリテンションを解消するアンチセンスオリゴヌクレオチド |
EP3724333A2 (en) | 2017-12-11 | 2020-10-21 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating fndc3b expression |
WO2019115417A2 (en) | 2017-12-12 | 2019-06-20 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating rb1 expression |
EP3724332A1 (en) | 2017-12-14 | 2020-10-21 | CRISPR Therapeutics AG | Novel rna-programmable endonuclease systems and their use in genome editing and other applications |
US11725208B2 (en) | 2017-12-14 | 2023-08-15 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
EP3724355A1 (en) | 2017-12-15 | 2020-10-21 | Novartis AG | Polya tail length analysis of rna by mass spectrometry |
BR112020012088A2 (pt) | 2017-12-18 | 2020-11-17 | Alnylam Pharmaceuticals, Inc. | composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos |
BR112020012523A2 (pt) | 2017-12-21 | 2020-11-24 | F. Hoffmann-La Roche Ag | diagnóstico complementar para antagonistas de rna htra1 |
US20200332289A1 (en) | 2017-12-22 | 2020-10-22 | Roche Innovation Center Copenhagen A/S | Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage |
TW201929870A (zh) | 2017-12-22 | 2019-08-01 | 丹麥商羅氏創新中心哥本哈根有限公司 | 包含二硫代磷酸酯核苷間連結之寡核苷酸 |
US11597926B2 (en) | 2017-12-22 | 2023-03-07 | Roche Innovation Center Copenhagen A/S | Thiophosphoramidites |
CN111699258A (zh) | 2018-01-10 | 2020-09-22 | 哥本哈根罗氏创新中心 | 用于调控pias4表达的寡核苷酸 |
WO2019137974A1 (en) | 2018-01-12 | 2019-07-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating gsk3b expression |
KR20200140240A (ko) | 2018-01-12 | 2020-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도 |
KR20200109338A (ko) | 2018-01-12 | 2020-09-22 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 알파-시누클레인 안티센스 올리고뉴클레오티드 및 이의 용도 |
SG11202006526YA (en) | 2018-01-12 | 2020-08-28 | Bristol Myers Squibb Co | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
MX2020007369A (es) | 2018-01-15 | 2020-10-28 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de dnm2. |
WO2019141656A1 (en) | 2018-01-17 | 2019-07-25 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating erc1 expression |
US20210095277A1 (en) | 2018-01-18 | 2021-04-01 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting srebp1 |
WO2019145386A1 (en) | 2018-01-26 | 2019-08-01 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating csnk1d expression |
PE20211197A1 (es) | 2018-02-09 | 2021-07-01 | Genentech Inc | Oligonucleotidos para modular la expresion de tmem106b |
JP2021513508A (ja) | 2018-02-12 | 2021-05-27 | インテアールエヌエー テクノロジーズ ビー.ヴイ.InteRNA Technologies B.V. | 抗がんマイクロrna及びその脂質製剤 |
CA3090901A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
KR20200140805A (ko) | 2018-02-21 | 2020-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | Camk2d 안티센스 올리고뉴클레오티드 및 그의 용도 |
CA3091857A1 (en) | 2018-02-26 | 2019-08-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
JP6884268B2 (ja) | 2018-03-09 | 2021-06-09 | 第一三共株式会社 | 糖原病Ia型治療薬 |
WO2019183150A1 (en) | 2018-03-19 | 2019-09-26 | Casebia Therapeutics Limited Liability Partnership | Novel rna-programmable endonuclease systems and uses thereof |
WO2019182037A1 (ja) | 2018-03-20 | 2019-09-26 | 国立大学法人東京工業大学 | 毒性が低減されたアンチセンスオリゴヌクレオチド |
PE20211912A1 (es) | 2018-04-05 | 2021-09-28 | Centre Nat Rech Scient | Uso de inhibidores de fubp1 para el tratamiento de infeccion de virus de hepatitis b |
EP3553182A1 (en) | 2018-04-11 | 2019-10-16 | Université de Bourgogne | Detection method of somatic genetic anomalies, combination of capture probes and kit of detection |
AU2019266207A1 (en) | 2018-05-07 | 2020-12-17 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
WO2019215067A1 (en) | 2018-05-07 | 2019-11-14 | Roche Innovation Center Copenhagen A/S | Massively parallel discovery methods for oligonucleotide therapeutics |
EP3790971A1 (en) | 2018-05-08 | 2021-03-17 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating myh7 expression |
MX2020011913A (es) | 2018-05-09 | 2021-01-29 | Ionis Pharmaceuticals Inc | Compuestos y metodos para la reduccion de la expresion de fxi. |
TW202016304A (zh) | 2018-05-14 | 2020-05-01 | 美商阿尼拉製藥公司 | 血管收縮素原(AGT)iRNA組成物及其使用方法 |
EP3793685A1 (en) | 2018-05-18 | 2021-03-24 | F. Hoffmann-La Roche AG | Pharmaceutical compositions for treatment of microrna related diseases |
WO2019224172A1 (en) | 2018-05-25 | 2019-11-28 | Roche Innovation Center Copenhagen A/S | Novel process for making allofuranose from glucofuranose |
EP3802824A1 (en) | 2018-06-05 | 2021-04-14 | F. Hoffmann-La Roche AG | Oligonucleotides for modulating atxn2 expression |
CN112218950A (zh) | 2018-06-13 | 2021-01-12 | 第一三共株式会社 | 心肌损伤治疗药 |
BR112020026073A2 (pt) | 2018-06-21 | 2021-03-23 | F. Hoffmann-La Roche Ag | método para fornecer um par de ligação, composição líquida, uso de uma composição e kit para realizar um imunoensaio heterogêneo |
WO2020007700A1 (en) | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting spi1 |
WO2020007772A1 (en) | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting gbp-1 |
WO2020007702A1 (en) | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting bcl2l11 |
BR112020026973A2 (pt) | 2018-07-03 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modulação da expressão tau |
WO2020007889A1 (en) | 2018-07-05 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting stat1 |
WO2020007826A1 (en) | 2018-07-05 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting mbtps1 |
WO2020011743A1 (en) | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting mafb |
WO2020011653A1 (en) | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting kynu |
WO2020011869A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting tlr2 |
WO2020011745A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting cers6 |
WO2020011744A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting cers5 |
SG11202100348SA (en) | 2018-07-13 | 2021-02-25 | Hoffmann La Roche | Oligonucleotides for modulating rtel1 expression |
JOP20210018A1 (ar) | 2018-07-25 | 2021-01-21 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير الوراثي عن atxn2 |
US20210308170A1 (en) | 2018-07-27 | 2021-10-07 | Osaka University | Composition for suppression of aging, prevention, amelioration, or treatment of an age-related disease or symptom, or extension of lifespan |
JP6544783B1 (ja) | 2018-07-31 | 2019-07-17 | 学校法人 岩手医科大学 | がんの診断のためのプローブ/プライマーライブラリー |
EP3830102B1 (en) | 2018-07-31 | 2022-06-08 | Roche Innovation Center Copenhagen A/S | Oligonucleotides comprising a phosphorotrithioate internucleoside linkage |
KR20210041537A (ko) | 2018-07-31 | 2021-04-15 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 포스포로트리티오에이트 뉴클레오사이드간 연결을 포함하는 올리고뉴클레오타이드 |
EP3830301A1 (en) | 2018-08-01 | 2021-06-09 | Mammoth Biosciences, Inc. | Programmable nuclease compositions and methods of use thereof |
EA202190528A1 (ru) | 2018-08-13 | 2021-04-23 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ АГЕНТОВ дцРНК ВИРУСА ГЕПАТИТА B (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
US20210348162A1 (en) | 2018-08-16 | 2021-11-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
JP2021535204A (ja) | 2018-08-20 | 2021-12-16 | ロジコン, インコーポレイテッド | Scn1a脳症の治療のためのscn2aを標的とするアンチセンスオリゴヌクレオチド |
WO2020038973A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting sptlc1 |
WO2020038968A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
WO2020038976A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting usp8 |
WO2020038971A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting vcan |
EP3844274A1 (en) | 2018-08-28 | 2021-07-07 | Roche Innovation Center Copenhagen A/S | Neoantigen engineering using splice modulating compounds |
EP3620519A1 (en) | 2018-09-04 | 2020-03-11 | F. Hoffmann-La Roche AG | Use of isolated milk extracellular vesicles for delivering oligonucleotides orally |
EP3620520A1 (en) | 2018-09-10 | 2020-03-11 | Universidad del Pais Vasco | Novel target to treat a metabolic disease in an individual |
US20220056220A1 (en) | 2018-09-14 | 2022-02-24 | Northwestern University | Programming protein polymerization with dna |
WO2020060986A1 (en) | 2018-09-18 | 2020-03-26 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
TW202023573A (zh) | 2018-09-19 | 2020-07-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
EP3856907A1 (en) | 2018-09-28 | 2021-08-04 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
CN112969709A (zh) | 2018-11-01 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 靶向tia1的反义寡核苷酸 |
BR112021009168A2 (pt) | 2018-11-12 | 2021-08-17 | Mitsubishi Tanabe Pharma Corporation | alna de ácido nucleico artificial reticulado |
EP3880821A4 (en) | 2018-11-15 | 2023-01-25 | Ionis Pharmaceuticals, Inc. | IRF5 EXPRESSION MODULATORS |
WO2020099533A1 (en) | 2018-11-16 | 2020-05-22 | F. Hoffmann-La Roche Ag | Streptavidin-coated solid phases with a member of a binding pair |
WO2020106996A1 (en) | 2018-11-21 | 2020-05-28 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing prion expression |
WO2020104492A1 (en) | 2018-11-22 | 2020-05-28 | Roche Innovation Center Copenhagen A/S | Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides |
WO2020109344A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Occular administration device for antisense oligonucleotides |
WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
WO2020118259A1 (en) | 2018-12-06 | 2020-06-11 | Northwestern University | Protein crystal engineering through dna hybridization interactions |
CN113631709A (zh) | 2018-12-20 | 2021-11-09 | 普拉克西斯精密药物股份有限公司 | 用于治疗kcnt1相关病症的组合物和方法 |
WO2020136125A2 (en) | 2018-12-21 | 2020-07-02 | Boehringer Ingelheim International Gmbh | Antisense oligonucleotides targeting card9 |
WO2020142754A2 (en) | 2019-01-04 | 2020-07-09 | Mammoth Biosciences, Inc. | Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection |
MX2021008628A (es) | 2019-01-16 | 2021-11-17 | Genzyme Corp | Composiciones de arni para serpinc1 y metodos de uso de las mismas. |
DE102019000490A1 (de) | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
JP2022518500A (ja) | 2019-01-25 | 2022-03-15 | エフ.ホフマン-ラ ロシュ アーゲー | 経口薬物送達のための脂質小胞 |
MX2021009259A (es) | 2019-02-06 | 2021-08-24 | Synthorx Inc | Conjugados de il-2 y metodos de uso del mismo. |
CA3130431A1 (en) | 2019-02-20 | 2020-08-27 | Roche Innovation Center Copenhagen A/S | Phosphonoacetate gapmer oligonucleotides |
WO2020169696A1 (en) | 2019-02-20 | 2020-08-27 | Roche Innovation Center Copenhagen A/S | Novel phosphoramidites |
JP2022522430A (ja) | 2019-02-26 | 2022-04-19 | ロシュ イノベーション センター コペンハーゲン エーエス | オリゴヌクレオチドの製剤化方法 |
MX2021010152A (es) | 2019-02-27 | 2021-09-14 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de malat1. |
US20220184216A1 (en) | 2019-03-05 | 2022-06-16 | Hoffmann-La Roche Inc. | Intracellular targeting of molecules |
MX2021010559A (es) | 2019-03-07 | 2021-12-15 | Univ California | Polipéptidos efectores de crispr-cas y métodos de uso de estos. |
MA55297A (fr) | 2019-03-12 | 2022-01-19 | Bayer Healthcare Llc | Nouveaux systèmes d'endonucléase à arn programmable haute fidélité et leurs utilisations |
EP3981431A4 (en) | 2019-03-14 | 2023-06-28 | Rena Therapeutics Inc. | Nucleic acid complex for modulating ihh expression |
MX2021011242A (es) | 2019-03-21 | 2022-01-19 | Codiak Biosciences Inc | Conjugados de vesícula extracelular y usos de estos. |
JP2022527105A (ja) | 2019-03-29 | 2022-05-30 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Ube3a-atsを調節するための化合物及び方法 |
CA3198029A1 (en) | 2019-03-29 | 2020-10-08 | Mitsubishi Tanabe Pharma Corporation | Compound, method and pharmaceutical composition for modulating expression of dux4 |
WO2020206115A2 (en) | 2019-04-03 | 2020-10-08 | Bristol-Myers Squibb Company | Angptl2 antisense oligonucleotides and uses thereof |
US11286485B2 (en) | 2019-04-04 | 2022-03-29 | Hoffmann-La Roche Inc. | Oligonucleotides for modulating ATXN2 expression |
WO2020201339A1 (en) | 2019-04-04 | 2020-10-08 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating atxn2 expression |
WO2020212301A1 (en) | 2019-04-16 | 2020-10-22 | Roche Innovation Center Copenhagen A/S | Novel process for preparing nucleotide p(v) monomers |
JP2022530537A (ja) | 2019-04-30 | 2022-06-29 | ロシュ イノベーション センター コペンハーゲン エーエス | レニウムキレート化mag3オリゴヌクレオチドを調製するための新規の方法 |
WO2020227395A2 (en) | 2019-05-06 | 2020-11-12 | University Of Massachusetts | Anti-c9orf72 oligonucleotides and related methods |
US20220211743A1 (en) | 2019-05-17 | 2022-07-07 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
CA3140112A1 (en) | 2019-05-31 | 2020-12-03 | Streck, Inc. | Detection of antibiotic resistance genes |
CN113939592A (zh) | 2019-06-05 | 2022-01-14 | 学校法人福冈大学 | 导入了化学修饰核酸的稳定型目标编辑向导rna |
EP3980539A1 (en) | 2019-06-06 | 2022-04-13 | F. Hoffmann-La Roche AG | Antisense oligonucleotides targeting atxn3 |
KR20220005571A (ko) | 2019-06-07 | 2022-01-13 | 에프. 호프만-라 로슈 아게 | 전부 lna 올리고뉴클레오티드 혼성화 |
JP2022538784A (ja) | 2019-06-14 | 2022-09-06 | ザ スクリプス リサーチ インスティテュート | 半合成生物における複製、転写および翻訳のための試薬ならびに方法 |
US20220315617A1 (en) | 2019-06-19 | 2022-10-06 | Yamasa Corporation | Crosslinked Nucleoside Intermediate Crystal And Method For Producing Same, And Method For Producing Crosslinked Nucleoside Amidite |
CN114080238A (zh) | 2019-06-26 | 2022-02-22 | 神户天然物化学株式会社 | 抑制肌肉生长抑制素基因的mRNA的产生的核酸药物 |
CN110204583B (zh) * | 2019-07-01 | 2021-03-23 | 中国人民解放军军事科学院军事医学研究院 | 修饰核苷、核苷酸和修饰核酸聚合物及其制备方法和应用 |
WO2021005223A1 (en) | 2019-07-10 | 2021-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
US20220364086A1 (en) | 2019-07-12 | 2022-11-17 | Daiichi Sankyo Company, Limited | ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA |
EP3956450A4 (en) | 2019-07-26 | 2022-11-16 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR MODULATION OF GFAP |
US20220267778A1 (en) | 2019-07-30 | 2022-08-25 | Shionogi & Co., Ltd. | Nucleic acid drug targeting murf1 |
WO2021022108A2 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021022109A1 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
EP4013870A1 (en) | 2019-08-13 | 2022-06-22 | Alnylam Pharmaceuticals, Inc. | Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof |
MX2022001770A (es) | 2019-08-14 | 2022-05-20 | Codiak Biosciences Inc | Vesícula extracelular unida a moléculas y usos de esta. |
EP4013872A1 (en) | 2019-08-14 | 2022-06-22 | Codiak BioSciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
JP2022544289A (ja) | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ, インコーポレイテッド | Stat6を標的とする細胞外小胞-aso構築物 |
WO2021030773A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicle-nlrp3 antagonist |
JP2022544934A (ja) | 2019-08-14 | 2022-10-24 | コディアック バイオサイエンシーズ, インコーポレイテッド | Stat3-アンチセンスオリゴヌクレオチドを含む細胞外小胞 |
AU2020330133A1 (en) | 2019-08-14 | 2022-03-17 | Lonza Sales Ag | Extracellular vesicle-ASO constructs targeting CEBP/beta |
WO2021030778A1 (en) | 2019-08-15 | 2021-02-18 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds and uses thereof |
MX2022002689A (es) | 2019-09-03 | 2022-04-07 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2). |
TW202123973A (zh) | 2019-09-10 | 2021-07-01 | 日商第一三共股份有限公司 | 用於肝臟遞送之GalNAc-寡核苷酸結合物及製造方法 |
IT201900017234A1 (it) | 2019-09-25 | 2021-03-25 | Int Centre For Genetic Engineering And Biotechnology | Anti-miRNA per il trattamento del leiomioma |
EP4034247A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
CN110590886B (zh) * | 2019-09-26 | 2021-03-23 | 中国人民解放军军事科学院军事医学研究院 | 修饰核苷、核苷酸和核酸聚合物及其制备方法与应用 |
EP4038189A1 (en) | 2019-10-04 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
WO2021074772A1 (en) | 2019-10-14 | 2021-04-22 | Astrazeneca Ab | Modulators of pnpla3 expression |
WO2021074657A1 (en) | 2019-10-17 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination treatment for cystic fibrosis |
TW202128704A (zh) * | 2019-10-18 | 2021-08-01 | 日商第一三共股份有限公司 | 雙環亞磷醯胺之製造方法 |
EP4045652A1 (en) | 2019-10-18 | 2022-08-24 | Alnylam Pharmaceuticals, Inc. | Solute carrier family member irna compositions and methods of use thereof |
EP4048793A1 (en) | 2019-10-22 | 2022-08-31 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
EP4052730A4 (en) * | 2019-10-28 | 2023-06-14 | National University Corporation Tokai National Higher Education and Research System | NUCLEOSIDE DERIVATIVE AND USE THEREOF |
AR120341A1 (es) | 2019-11-01 | 2022-02-09 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO |
US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
JP2023500681A (ja) | 2019-11-06 | 2023-01-10 | アルニラム ファーマスーティカルズ インコーポレイテッド | 肝臓外送達 |
EP4055165A1 (en) | 2019-11-06 | 2022-09-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
CN114981431A (zh) | 2019-11-13 | 2022-08-30 | 阿尔尼拉姆医药品有限公司 | 用于治疗血管紧张素原(agt)相关病症的方法和组合物 |
WO2021099394A1 (en) | 2019-11-19 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antisense oligonucleotides and their use for the treatment of cancer |
EP4061945A1 (en) | 2019-11-22 | 2022-09-28 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
CN115335521A (zh) | 2019-11-27 | 2022-11-11 | 克里斯珀医疗股份公司 | 合成rna分子的方法 |
WO2021119275A1 (en) | 2019-12-11 | 2021-06-17 | Intellia Therapeutics, Inc. | Modified guide rnas for gene editing |
EP4073251A1 (en) | 2019-12-13 | 2022-10-19 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
WO2021126734A1 (en) | 2019-12-16 | 2021-06-24 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
AU2020407267A1 (en) | 2019-12-18 | 2022-06-16 | F. Hoffmann-La Roche Ag | Methods of sequencing by synthesis using a consecutive labeling scheme |
JP2023506540A (ja) | 2019-12-19 | 2023-02-16 | エフ. ホフマン-ラ ロシュ エージー. | B型肝炎ウイルス感染を処置するためのscamp3阻害剤の使用 |
CN115516091A (zh) | 2019-12-19 | 2022-12-23 | 豪夫迈·罗氏有限公司 | Cops3抑制剂用于治疗乙型肝炎病毒感染的用途 |
EP4077669A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of sbds inhibitors for treating hepatitis b virus infection |
CN114867856A (zh) | 2019-12-19 | 2022-08-05 | 豪夫迈·罗氏有限公司 | Saraf抑制剂用于治疗乙型肝炎病毒感染的用途 |
CN114901821A (zh) | 2019-12-19 | 2022-08-12 | 豪夫迈·罗氏有限公司 | Sept9抑制剂用于治疗乙型肝炎病毒感染的用途 |
CN114829603A (zh) | 2019-12-20 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 用于抑制scn9a表达的增强寡核苷酸 |
WO2021130270A1 (en) | 2019-12-24 | 2021-07-01 | F. Hoffmann-La Roche Ag | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
JP2023509870A (ja) | 2019-12-24 | 2023-03-10 | エフ. ホフマン-ラ ロシュ アーゲー | Hbvの処置のためのhbvを標的とする治療用オリゴヌクレオチドとtlr7アゴニストとの医薬組合せ |
US20230127437A1 (en) | 2020-01-31 | 2023-04-27 | Sanwa Kagaku Kenkyusho Co., Ltd. | Antisense oligonucleotide of atn1 |
WO2021158810A1 (en) | 2020-02-05 | 2021-08-12 | Bristol-Myers Squibb Company | Oligonucleotides for splice modulation of camk2d |
CA3170377A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
CN115397989A (zh) | 2020-02-18 | 2022-11-25 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白C3(APOC3)iRNA组合物及其使用方法 |
TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
TW202140787A (zh) | 2020-02-28 | 2021-11-01 | 美商Ionis製藥公司 | 用於調節smn2之化合物及方法 |
WO2021170697A1 (en) | 2020-02-28 | 2021-09-02 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating cd73 exon 7 splicing |
WO2021177418A1 (ja) | 2020-03-04 | 2021-09-10 | 日産化学株式会社 | Calm2のアンチセンスオリゴヌクレオチド |
EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
EP4114949A1 (en) | 2020-03-06 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin (ttr) |
WO2021178736A1 (en) | 2020-03-06 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
CA3175125A1 (en) | 2020-03-11 | 2021-09-16 | Biocomber Co., Ltd. | Single-stranded nucleic acid molecule for inducing -1 frameshift and composition |
WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
WO2021188611A1 (en) | 2020-03-18 | 2021-09-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
CN116209759A (zh) | 2020-03-26 | 2023-06-02 | 阿尔尼拉姆医药品有限公司 | 冠状病毒iRNA组合物及其使用方法 |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
KR20220161436A (ko) | 2020-03-31 | 2022-12-06 | 얀센 바이오파마, 인코퍼레이트. | 올리고뉴클레오티드 및 관련 화합물의 합성 |
BR112022020145A2 (pt) | 2020-04-06 | 2023-01-03 | Alnylam Pharmaceuticals Inc | Composições e métodos para silenciamento da expressão de myoc |
WO2021207189A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing scn9a expression |
WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
EP4133077A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
KR20230018377A (ko) | 2020-04-27 | 2023-02-07 | 알닐람 파마슈티칼스 인코포레이티드 | 아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법 |
KR20230017789A (ko) | 2020-04-30 | 2023-02-06 | 알닐람 파마슈티칼스 인코포레이티드 | 보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법 |
US20230287410A1 (en) | 2020-05-11 | 2023-09-14 | Stoke Therapeutics, Inc. | Opa1 antisense oligomers for treatment of conditions and diseases |
WO2021231210A1 (en) | 2020-05-11 | 2021-11-18 | Genentech, Inc. | Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same |
EP4149486A1 (en) | 2020-05-11 | 2023-03-22 | Genentech, Inc. | Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same |
EP4150084A1 (en) | 2020-05-11 | 2023-03-22 | Genentech, Inc. | Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same |
US20230227824A1 (en) | 2020-05-12 | 2023-07-20 | Mitsubishi Tanabe Pharma Corporation | Compound, method and pharmaceutical composition for regulating expression of ataxin 3 |
EP4150083A1 (en) | 2020-05-13 | 2023-03-22 | F. Hoffmann-La Roche AG | Oligonucleotide agonists targeting progranulin |
EP4150077A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
EP4150078A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
EP4150076A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
EP4150090A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
CA3162416C (en) | 2020-05-15 | 2023-07-04 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
EP4150089A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1) |
EP4153746A1 (en) | 2020-05-21 | 2023-03-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
CN115884777A (zh) | 2020-05-22 | 2023-03-31 | 豪夫迈·罗氏有限公司 | 用于card9的剪接调节的寡核苷酸 |
AR122534A1 (es) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3 |
WO2021249993A1 (en) | 2020-06-09 | 2021-12-16 | Roche Innovation Center Copenhagen A/S | Guanosine analogues for use in therapeutic polynucleotides |
EP4162050A1 (en) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
CN116209760A (zh) | 2020-06-18 | 2023-06-02 | 阿尔尼拉姆医药品有限公司 | 黄嘌呤脱氢酶(XDH)iRNA组合物及其使用方法 |
AR122731A1 (es) | 2020-06-26 | 2022-10-05 | Hoffmann La Roche | Oligonucleótidos mejorados para modular la expresión de fubp1 |
CN111732623B (zh) * | 2020-06-30 | 2022-01-18 | 中国科学院化学研究所 | 一种三异丙基硅乙炔修饰的脱氧胞苷亚磷酰胺单体及其制备方法与应用 |
CN115803333A (zh) | 2020-07-02 | 2023-03-14 | 生命技术公司 | 三核苷酸帽类似物、其制备和用途 |
WO2022008935A1 (en) | 2020-07-10 | 2022-01-13 | Horizon Discovery Limited | Method for producing genetically modified cells |
US20230257745A1 (en) | 2020-07-10 | 2023-08-17 | Alnylam Pharmaceuticals, Inc. | Circular siRNAs |
BR112023000428A2 (pt) | 2020-07-10 | 2023-03-14 | Inst Nat Sante Rech Med | Métodos e composições para tratar epilepsia |
WO2022018155A1 (en) | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Lna oligonucleotides for splice modulation of stmn2 |
WO2022018187A1 (en) | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting rna binding protein sites |
WO2022024833A1 (ja) | 2020-07-28 | 2022-02-03 | 神戸天然物化学株式会社 | アンギオテンシン変換酵素2遺伝子のエクソンのスキッピングを誘導するアンチセンス核酸 |
JP2023538630A (ja) | 2020-08-21 | 2023-09-08 | エフ. ホフマン-ラ ロシュ アーゲー | B型肝炎ウイルス感染症を処置するためのa1cf阻害剤の使用 |
TW202227102A (zh) | 2020-09-22 | 2022-07-16 | 瑞典商阿斯特捷利康公司 | 治療脂肪肝病之方法 |
EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
TW202229552A (zh) | 2020-10-05 | 2022-08-01 | 美商艾拉倫製藥股份有限公司 | G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法 |
US20230364127A1 (en) | 2020-10-06 | 2023-11-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
US20240018516A1 (en) | 2020-11-06 | 2024-01-18 | Sumitomo Pharma Co., Ltd. | Agent for Regulating Expression and/or Function of RPS25 Gene |
JP2023549500A (ja) | 2020-11-13 | 2023-11-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 凝固第V因子(F5)iRNA組成物およびその使用方法 |
EP4136092A4 (en) | 2020-11-18 | 2023-10-11 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION |
CA3202569A1 (en) | 2020-11-18 | 2022-05-27 | Lemba Bv | Umlilo antisense transcription inhibitors |
CA3202708A1 (en) | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
WO2022117747A2 (en) | 2020-12-03 | 2022-06-09 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting atxn3 |
WO2022117745A1 (en) | 2020-12-03 | 2022-06-09 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting atxn3 |
JP2023553069A (ja) | 2020-12-08 | 2023-12-20 | エフ. ホフマン-ラ ロシュ アーゲー | ホスホロジチオエートオリゴヌクレオチドの新規合成 |
EP4259795A1 (en) | 2020-12-08 | 2023-10-18 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
JPWO2022124345A1 (es) | 2020-12-08 | 2022-06-16 | ||
GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
KR20230118076A (ko) * | 2020-12-11 | 2023-08-10 | 야마사 쇼유 가부시키가이샤 | 시토신형 가교형 뉴클레오시드 아미다이트 결정 및 그 제조 방법 |
WO2022129320A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides for targeting progranulin |
EP4267734A1 (en) | 2020-12-22 | 2023-11-01 | F. Hoffmann-La Roche AG | Oligonucleotides targeting xbp1 |
WO2022147214A2 (en) | 2020-12-31 | 2022-07-07 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
EP4271695A2 (en) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | 2'-modified nucleoside based oligonucleotide prodrugs |
WO2022150260A1 (en) | 2021-01-05 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 rtel1 表現之增強型寡核苷酸 |
IL304956A (en) | 2021-02-12 | 2023-10-01 | Merand Pharmaceuticals Inc | Materials, compositions and methods for treating hypoxia and ischemia-related disorders |
WO2022174000A2 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
WO2022178149A2 (en) | 2021-02-17 | 2022-08-25 | Codiak Biosciences, Inc. | Extracellular vesicle-nlrp3 antagonist |
KR20230146603A (ko) | 2021-02-17 | 2023-10-19 | 론자 세일즈 아게 | 최적화 링커와 고정 모이어티를 통해 생물학적 활성 분자에 연결된 세포외 소포체 |
JP2024509783A (ja) | 2021-02-25 | 2024-03-05 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | プリオンタンパク質(prnp)irna組成物およびその使用方法 |
WO2022181532A1 (ja) | 2021-02-26 | 2022-09-01 | 学校法人神戸学院 | ミオスタチンのスプライシングバリアントを発現させる核酸医薬 |
WO2022182574A1 (en) | 2021-02-26 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022187435A1 (en) | 2021-03-04 | 2022-09-09 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
EP4304640A1 (en) | 2021-03-12 | 2024-01-17 | Northwestern University | Antiviral vaccines using spherical nucleic acids |
WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
AU2022242781A1 (en) | 2021-03-26 | 2023-10-26 | Neumirna Therapeutics Aps | Microrna-27b inhibitors |
KR20230170690A (ko) | 2021-03-26 | 2023-12-19 | 뉴미르나 테라퓨틱스 에이피에스 | MicroRNA-134 억제제들 |
CA3214499A1 (en) | 2021-03-29 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
KR20240009393A (ko) | 2021-03-31 | 2024-01-22 | 엔트라다 테라퓨틱스, 인크. | 사이클릭 세포 침투 펩티드 |
WO2022212153A1 (en) | 2021-04-01 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
WO2022212884A1 (en) | 2021-04-01 | 2022-10-06 | Codiak Biosciences, Inc. | Extracellular vesicle compositions |
WO2022221514A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
EP4330392A1 (en) | 2021-04-26 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof |
WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
WO2022240760A2 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING |
AU2022271873A1 (en) | 2021-05-10 | 2024-01-04 | Entrada Therapeutics, Inc. | Compositions and methods for intracellular therapeutics |
WO2022240721A1 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity |
EP4341401A1 (en) | 2021-05-18 | 2024-03-27 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
WO2022246023A1 (en) | 2021-05-20 | 2022-11-24 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
EP4353266A1 (en) | 2021-05-31 | 2024-04-17 | Rena Therapeutics Inc. | Ligand-bound nucleic acid complex |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
WO2022256395A1 (en) | 2021-06-02 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
AU2022284878A1 (en) | 2021-06-04 | 2024-01-18 | Translate Bio, Inc. | Assay for quantitative assessment of mrna capping efficiency |
BR112023025224A2 (pt) | 2021-06-04 | 2024-02-27 | Alnylam Pharmaceuticals Inc | Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos |
EP4347824A1 (en) | 2021-06-04 | 2024-04-10 | Neumirna Therapeutics ApS | Antisense oligonucleotides targeting adenosine kinase |
WO2022260939A2 (en) | 2021-06-08 | 2022-12-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders |
CN117441018A (zh) | 2021-06-08 | 2024-01-23 | 豪夫迈·罗氏有限公司 | 寡核苷酸颗粒蛋白前体激动剂 |
TW202317764A (zh) | 2021-06-10 | 2023-05-01 | 美商英特利亞醫療公司 | 用於基因編輯之包含內部連接子之經修飾引導rna |
EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
BR112023023768A2 (pt) | 2021-06-11 | 2024-02-27 | Bayer Ag | Sistemas de endonucleases programáveis por rna tipo v |
BR112023027308A2 (pt) | 2021-06-22 | 2024-03-12 | AcuraStem Incorporated | Oligonucleotídeos antisense pikfyve |
IL309001A (en) | 2021-06-23 | 2024-02-01 | Entrada Therapeutics Inc | Antisense compounds and methods for targeting CUG repeats |
US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
AU2022303164A1 (en) | 2021-06-30 | 2024-01-18 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2023287141A1 (ko) | 2021-07-12 | 2023-01-19 | 주식회사 씨젠 | 용기에 수용된 용액의 높이를 결정하는 방법 및 시스템 |
WO2023003805A1 (en) | 2021-07-19 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
KR20240036041A (ko) | 2021-07-21 | 2024-03-19 | 알닐람 파마슈티칼스 인코포레이티드 | 대사 장애-연관 표적 유전자 iRNA 조성물 및 이의 사용 방법 |
US20230125137A1 (en) | 2021-07-21 | 2023-04-27 | AcuraStem, Inc. | Unc13a antisense oligonucleotides |
IL309905A (en) | 2021-07-23 | 2024-03-01 | Alnylam Pharmaceuticals Inc | IRNA compositions in β-catenin (CTNNB1) and methods of using them |
WO2023009687A1 (en) | 2021-07-29 | 2023-02-02 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
CN117795074A (zh) | 2021-08-03 | 2024-03-29 | 阿尔尼拉姆医药品有限公司 | 转甲状腺素蛋白(TTR)iRNA组合物和其使用方法 |
TW202337474A (zh) | 2021-08-04 | 2023-10-01 | 美商艾拉倫製藥股份有限公司 | 用於緘默血管收縮素原(AGT)的iRNA組成物及方法 |
AR126771A1 (es) | 2021-08-13 | 2023-11-15 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi CONTRA EL FACTOR XII (F12) Y SUS MÉTODOS DE USO |
WO2023021046A1 (en) | 2021-08-16 | 2023-02-23 | Vib Vzw | Oligonucleotides for modulating synaptogyrin-3 expression |
AU2022329834A1 (en) | 2021-08-17 | 2024-03-07 | Korea Advanced Institute Of Science And Technology | Antisense oligonucleotide targeting cav3.1 gene and uses thereof |
CA3228833A1 (en) | 2021-08-19 | 2023-02-23 | Neumirna Therapeutics Aps | Antisense oligonucleotides targeting adenosine kinase |
CA3229661A1 (en) | 2021-09-01 | 2023-03-09 | Xiang Li | Compounds and methods for skipping exon 44 in duchenne muscular dystrophy |
WO2023034870A2 (en) | 2021-09-01 | 2023-03-09 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing dmpk expression |
EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
WO2023043280A1 (ko) | 2021-09-17 | 2023-03-23 | 주식회사 씨젠 | 합성 비자연 염기를 포함하는 태그 올리고뉴클레오타이드를 이용한 타겟 핵산 서열의 검출 |
WO2023044370A2 (en) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
WO2023044094A1 (en) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
AR127158A1 (es) | 2021-09-29 | 2023-12-27 | Hoffmann La Roche | Oligonucléotido antisentido para la edición de arn asociado a enfermedades de poliglutamina |
WO2023064530A1 (en) | 2021-10-15 | 2023-04-20 | Alnylam Pharmaceuticals, Inc. | Extra-hepatic delivery irna compositions and methods of use thereof |
WO2023069603A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
TW202334418A (zh) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 杭丁頓(HTT)iRNA劑組成物及其使用方法 |
WO2023076451A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
WO2023078883A1 (en) | 2021-11-03 | 2023-05-11 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating apolipoprotein e4 expression |
WO2023083906A2 (en) | 2021-11-11 | 2023-05-19 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
WO2023092060A1 (en) | 2021-11-18 | 2023-05-25 | Cornell University | Microrna-dependent mrna switches for tissue-specific mrna-based therapies |
WO2023092102A1 (en) | 2021-11-19 | 2023-05-25 | Sanegene Bio Usa Inc. | Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof |
WO2023104693A1 (en) | 2021-12-07 | 2023-06-15 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting actl6b |
GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
WO2023111336A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Oligonucleotide gba agonists |
WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
WO2023117738A1 (en) | 2021-12-20 | 2023-06-29 | F. Hoffmann-La Roche Ag | Threose nucleic acid antisense oligonucleotides and methods thereof |
WO2023122762A1 (en) | 2021-12-22 | 2023-06-29 | Camp4 Therapeutics Corporation | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas |
WO2023118068A1 (en) | 2021-12-23 | 2023-06-29 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2023141507A1 (en) | 2022-01-20 | 2023-07-27 | Genentech, Inc. | Antisense oligonucleotides for modulating tmem106b expression |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023152369A1 (en) | 2022-02-14 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis |
WO2023156652A1 (en) | 2022-02-21 | 2023-08-24 | F. Hoffmann-La Roche Ag | Antisense oligonucleotide |
WO2023212625A1 (en) | 2022-04-28 | 2023-11-02 | AcuraStem Incorporated | Syf2 antisense oligonucleotides |
WO2023220561A1 (en) | 2022-05-09 | 2023-11-16 | Sanegene Bio Usa Inc. | Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof |
WO2023217890A1 (en) | 2022-05-10 | 2023-11-16 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting cfp-elk1 intergene region |
WO2023220744A2 (en) | 2022-05-13 | 2023-11-16 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
WO2023222858A1 (en) | 2022-05-18 | 2023-11-23 | F. Hoffmann-La Roche Ag | Improved oligonucleotides targeting rna binding protein sites |
WO2023237587A1 (en) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2023240277A2 (en) | 2022-06-10 | 2023-12-14 | Camp4 Therapeutics Corporation | Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas |
WO2023242324A1 (en) | 2022-06-17 | 2023-12-21 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides for targeting progranulin |
WO2024006999A2 (en) | 2022-06-30 | 2024-01-04 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
WO2024031101A1 (en) | 2022-08-05 | 2024-02-08 | Sanegene Bio Usa Inc. | Double stranded rna targeting angiotensinogen (agt) and methods of use thereof |
WO2024039776A2 (en) | 2022-08-18 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Universal non-targeting sirna compositions and methods of use thereof |
EP4332221A1 (en) | 2022-08-29 | 2024-03-06 | Roche Innovation Center Copenhagen A/S | Threose nucleic acid antisense oligonucleotides and methods thereof |
EP4332239A1 (en) | 2022-08-30 | 2024-03-06 | Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. | Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis |
WO2024052403A1 (en) | 2022-09-06 | 2024-03-14 | F. Hoffmann-La Roche Ag | Double-stranded rna molecule for administration to the eye |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
WO2024073732A1 (en) | 2022-09-30 | 2024-04-04 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
WO2024073042A1 (en) | 2022-09-30 | 2024-04-04 | Entrada Therapeutics, Inc. | Ocular delivery of therapeutic agents |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1223831A (en) * | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
WO1990014353A1 (en) * | 1989-05-18 | 1990-11-29 | Microprobe Corporation | Crosslinking oligonucleotides |
US5177196A (en) * | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
DE4408528A1 (de) | 1994-03-14 | 1995-09-28 | Hoechst Ag | Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung |
US5965720A (en) * | 1994-03-18 | 1999-10-12 | Lynx Therapeutics, Inc. | Oligonucleotide N3'→P5' phosphoramidates |
US5681940A (en) | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
PT820483E (pt) | 1995-04-07 | 2001-03-30 | Mogens Havsteen Jakobsen | Metodo de imobilizacao fotoquimica de ligandos usando quinonas |
US6153745A (en) * | 1995-09-22 | 2000-11-28 | Amersham Pharmacia Biotech Uk Limited | Relating to mutagenesis of nucleic acids |
JP2002515738A (ja) * | 1996-01-23 | 2002-05-28 | アフィメトリックス,インコーポレイティド | 核酸分析法 |
JP3781879B2 (ja) * | 1996-11-18 | 2006-05-31 | 武 今西 | 新規ヌクレオチド類縁体 |
JP3756313B2 (ja) * | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
-
1998
- 1998-09-14 EP EP04020014A patent/EP1557424A1/en not_active Withdrawn
- 1998-09-14 EP EP10185895A patent/EP2341057A3/en not_active Withdrawn
- 1998-09-14 KR KR10-2000-7002608A patent/KR100414936B1/ko not_active IP Right Cessation
- 1998-09-14 WO PCT/DK1998/000393 patent/WO1999014226A2/en active Application Filing
- 1998-09-14 NZ NZ503765A patent/NZ503765A/en not_active IP Right Cessation
- 1998-09-14 EP EP10185908A patent/EP2341058A3/en not_active Withdrawn
- 1998-09-14 AU AU90633/98A patent/AU9063398A/en not_active Abandoned
- 1998-09-14 AT AT98942516T patent/ATE293123T1/de not_active IP Right Cessation
- 1998-09-14 DE DE69829760.1T patent/DE69829760T3/de not_active Expired - Lifetime
- 1998-09-14 JP JP2000511775A patent/JP4236812B2/ja not_active Expired - Lifetime
- 1998-09-14 ES ES98942516.0T patent/ES2242291T5/es not_active Expired - Lifetime
- 1998-09-14 EP EP10161457A patent/EP2253639A1/en not_active Withdrawn
- 1998-09-14 CA CA2303299A patent/CA2303299C/en not_active Expired - Lifetime
- 1998-09-14 DE DE04020014T patent/DE04020014T1/de active Pending
- 1998-09-14 IL IL13500098A patent/IL135000A0/xx unknown
- 1998-09-14 CN CNB988109557A patent/CN1273476C/zh not_active Expired - Lifetime
- 1998-09-14 EP EP98942516.0A patent/EP1015469B2/en not_active Expired - Lifetime
-
2000
- 2000-03-09 IL IL135000A patent/IL135000A/en not_active IP Right Cessation
-
2001
- 2001-07-05 HK HK01104632A patent/HK1033946A1/xx not_active IP Right Cessation
-
2007
- 2007-05-07 JP JP2007122900A patent/JP5677716B2/ja not_active Expired - Lifetime
- 2007-08-28 IL IL185569A patent/IL185569A/en not_active IP Right Cessation
- 2007-08-28 IL IL185568A patent/IL185568A/en not_active IP Right Cessation
- 2007-08-28 IL IL185570A patent/IL185570A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2242291T5 (es) | Análogos de nucleósidos bicíclicos y tricíclicos, nucleótidos y oligonucleótidos | |
CN106661577B (zh) | 反义核酸 | |
Dueholm et al. | Peptide nucleic acid (PNA) with a chiral backbone based on alanine | |
CA2329135C (en) | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | |
US20020068708A1 (en) | Oligonucleotide analogues | |
US20030077609A1 (en) | Modified oligonucleotides and uses thereof | |
IS6705A (is) | Aðferð til að ákvarða stig metýleringar afmarkaðra sýtósína í genamengi DNA í raðasamhenginu 5'-CPG-3' | |
EP2366803A3 (en) | Compositions and methods for detecting west nile virus | |
ES2192672T3 (es) | Nuevos analogos de nucleotidos. | |
WO2002006531A3 (en) | Nucleic acid hairpin probes and uses thereof | |
GB2284209A (en) | Nucleic acid analogue-induced transcription of RNA from a double-stranded DNA template | |
Kuwahara et al. | Direct PCR amplification of various modified DNAs having amino acids: convenient preparation of DNA libraries with high-potential activities for in vitro selection | |
CA2382631C (en) | Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids | |
ATE486956T1 (de) | T-zellrezeptor vb-db-jb-sequenz und verfahren für ihren nachweis | |
KR20020007359A (ko) | 프라이머 쌍들의 증폭 및 시퀀싱 및 그 이용 | |
ATE242261T1 (de) | Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen | |
JP2005529606A (ja) | ポリマー標識分子 | |
Eritja | Solid-phase synthesis of modified oligonucleotides | |
EP1258731A3 (en) | Reactive solid support for DNA fragment detection | |
JP6491233B2 (ja) | ハイブリダイゼーション安定化用核酸複合体、核酸ハイブリダイゼーションの安定化方法、アンチセンス核酸医薬品及びmicroRNA抑制剤 | |
Depecker et al. | Liquid-phase synthesis of a cyclic hexameric peptide nucleic acid | |
Murata et al. | Synthesis of a novel ester analog of nucleic acids bearing a serine backbone | |
Kuwahara et al. | Enzymatic incorporation of chemically-modified nucleotides into DNAs | |
CN112313513A (zh) | 具有均匀氢键合相互作用、同碱基对和异碱基对偏好以及错配辨别力的修饰核碱基 | |
KR101576565B1 (ko) | 비스pna를 이용한 핵산의 표지, 및 검출 또는 분석 방법및 키트, 및 이를 위한 비스pna |